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ABSTRACT  
The cannabinoid receptors CB1 and CB2, which belong to the rhodopsin family of GPCRs, are 
implicated in the pathology of various disease states. As drugs targeting these receptors remain 
limited, novel cannabinoid receptor ligands represent an unmet need with substantial therapeutic 
potential. We present here the construction and application of homology models of the human CB1 
and CB2 cannabinoid receptors based on the crystal structure of the human adenosine A2A receptor 
for the structure-based design of novel ligands based on the fenofibrate scaffold. Models were 
refined through molecular dynamic simulations in a lipid bilayer, and were validated via the 
prediction of known ligand binding affinities, enrichment studies and assessment of predicted 
ligand binding modes. These validated models were subsequently used in predicting the binding 
mode of fenofibrate derivatives to the cannabinoid receptors. The predicted binding mode of these 
fenofibrate derivatives to the CB2 receptor showed good agreement with known mutagenesis data, 
indicating the binding of these compounds to be stabilized primarily by hydrogen bonds with 
W5.43 and C7.42, aromatic stacking with F2.57, F3.36 and W6.48, and hydrophobic contact with 
F2.64, V3.32 and I5.47. A series of novel ligands was derived based on these findings, docked into 
our model, synthesized and pharmacologically evaluated at the CB2 receptor. The pharmacology of 
these ligands validated our modelling predictions and binding mode hypothesis, with several of 
these ligands showing unique pharmacology by binding in an allosteric manner. These findings 
may be used to guide the design of further derivatives and highlight the promise of the fenofibrate 
scaffold in the development of novel CB2 receptor ligands. 
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CB2  Cannabinoid receptor 2 
CHCl3  Chloroform 
CHO  Chinese Hamster Ovary 
CINV  Chemotherapy-induced nausea and vomiting 
CNS  Central nervous system 
DAG  Diacylglycerol 
DCE  1,2 dichloroethane 
DCM  Dichloromethane 
DIAD  Diisopropyl azodicarboxylate 
DMF  Dimethylformamide 
EDTA  Ethylenediaminetetraacetic acid 
EtOAc  Ethyl acetate 
EMEA  European Medicines Agency 
FAAH  Fatty acid amide hydrolase 
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1 INTRODUCTION 
1.1 G protein-coupled receptors 
1.1.1 Structure, function, and classification 
The G protein-coupled receptor (GPCR) superfamily is one of the largest and most varied family of 
proteins in the human genome, consisting of approximately 800 members (1). The receptors under 
this superfamily are diverse in both their function and the ligands that they bind, regulating a 
myriad of physiological processes, from smell and taste to the control of blood pressure, sleep 
regulation and pain. These processes are mediated by various extracellular ligands that include 
biogenic amines, peptides, ions and nucleotides, among others. Despite this diversity, all GPCRs 
share two common features.  Firstly, the overall structure of all GPCRs are similar: consisting of 
VHYHQWUDQVPHPEUDQHĮ-helices, an extracellular N-terminus, an intracellular C-terminus, and three 
interhelical loops on each side of the cell membrane (see Figure 1-1) (1,2). Hence, the GPCRs are 
DOVRNQRZQDV³-WUDQVPHPEUDQHUHFHSWRUV´DQG³KHSWDKHOLFDOUHFHSWRUV´although the term GPCR 
is by far more established. Secondly, as implied by their name, GPCRs are also able to interact with 
and signal through guanosine-nucleotide binding proteins (G proteins) of various subtypes, 
although this property has yet to be demonstrated for many GPCRs, particularly the orphan 
receptors (more than 100 GPCRs with currently no known ligand) (3).  
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Figure 1-1 Schematic structure of a typical G protein-coupled receptor. 
 
 Due to the vast variation present, there have been several classification systems used over 
the years to sort the GPCR superfamily, mostly utilizing sequence similarity and phylogenetic 
analysis as classification tools. Previously, one of the most frequently used classification systems 
divided the GPCRs according to the classes A to F, which represented rhodopsin-like, secretin-like, 
metabotropic glutamate-like, fungal pheromone, cAMP and frizzled/smoothened GPCRs 
respectively (4). This classification system was designed to include GPCRs from all species, and 
includes classes that do not appear in humans, such as the fungal pheromone and cAMP classes. 
More recently, Fredriksson et al presented the increasingly popular GRAFS classification system 
following phylogenetic analysis of the GPCR sequences found in the human genome (1). GRAFS 
itself is an acronym of the families identified, namely glutamate, rhodopsin, adhesion, 
frizzled/taste2, and smoothened. 
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1.1.2  Activation and signal transduction in GPCRs 
1.1.2.1 Pathways mediated through G proteins 
While it is becoming increasingly recognized that not all GPCRs currently classified as such may 
be able to interact with G proteins, the majority of the GPCRs still exploit these signal transduction 
pathways from which their name is derived. G proteins are heterotrimeric proteins whose activation 
is linked to guanosine diphosphate (GDP) - guanosine triphosphate (GTP) exchange, and are 
composed RIWKUHHVXEXQLWVĮȕDQGȖZLWKVHYHUDOVXEW\SHVRIHDFK (see Figure 1-2) (5).  
 
 
Figure 1-2 Diversity of GPCR ligands and signalling pathways. Taken from reference (6) 
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 ,Q WKH LQDFWLYH VWDWH WKH*ĮVXEXQLW FRQWDLQV D GDP molecule within its binding pocket. 
Following ligand binding, a conformational change is induced in the GPCR that allows for 
LQWHUDFWLRQRIWKHF\WRSODVPLFIDFHRIWKHUHFHSWRUZLWKWKH&WHUPLQXVRIWKH*ĮVXEXQLWZKLOHWKH
*ȕȖVXEXQLWVWDELOL]HVWKLVLQWHUIDFH (5,7). This in turn catalyses the exchange of GDP for GTP in 
WKH*ĮVXEXQLWDQGXSRQ*73ELQGLQJWKH*ĮVXEXQLWGLVVRFLDWHVIURPERWKUHFHSWRUDQGWKH*ȕȖ
subunit, proceeding to effect second messenger mechanisms within the cell (8). The G protein-
receptor complex is therefore transient in nature, as the much higher concentration of GTP within 
the cell ensures rapid exchange with GDP. The activated receptor is consequently able to interact 
with several other G proteins before its bound ligand dissociates, contributing to signal 
amplification (5,8). While the signalling cascades mediated through G proteins are complex, they 
FDQEURDGO\EHGLYLGHGLQWRPDLQIDPLOLHVEDVHGRQWKH*ĮVXEXQLW*S, Gi/o, Gq/11, and G12/13 (2). 
Specific receptors have specific preferences for the G proteins that they couple with, although it has 
been demonstrated that many GPCRs are able to activate several types of G proteins to a certain 
degree (5). 
 GS dissociation from the G protein results in the activation of the adenylyl cyclase pathway, 
leading to a cellular increase of cyclic adenosine monophosphate (cAMP) concentration and the 
subsequent activation of protein kinase A (PKA) (2,8). In contrast, Gi acts in an opposing manner 
on the same pathway, leading to an inhibition of adenylyl cyclase activity (2). The Gq subunit 
activates the enzyme phospholipase C, which in turn cleaves the cell membrane component 
phosphatidylinositol diphosphate (PIP2) into two second messengers, diacylglycerol (DAG) and 
inositol triphosphate (IP3) (2,8). This ultimately results in the activation of protein kinase C (PKC) 
and an increase in intracellular calcium levels, subsequently activating calcium-dependent and 
calmodulin-dependent protein kinases. 
 $OWKRXJK WKH *Į VXEXQLW KDV EHHQ PRUH H[WHQVLYHO\ VWXGLHG LQ * SURWHLQ-mediated 
signalOLQJ LW KDVHPHUJHG WKDW WKH*ȕȖGLPHU LWVHOIDFWLYDWHV or inhibits a vast range of proteins, 
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including adenylyl cyclase, G protein-activated inward rectifier K+ channels, and PKC, among 
others (9±13)  1RWDEO\ KRZHYHU KLJKHU FRQFHQWUDWLRQV RI WKH *ȕȖ GLPHU DUH UHTXLUHG EHIRUH D
VLJQLILFDQW UHVSRQVH LV JHQHUDWHG ZKHQ FRPSDUHG WR WKH *Į VXEXQLW DV KDV EHHQ shown 
experimentally for phospholipase C (14). This ability to mediate several pathways at once 
demonstrates the complexity involved in G protein signalling, allowing for the fine control of 
cellular processes. 
 
1.1.2.2 Signalling through G protein-independent pathways 
It has becoming increasingly evident in recent years that activated GPCRs may produce 
biochemical responses independent of heterotrimeric G proteins and the classical second 
messengers (6). These pathways may be mediated through other non-GPCR membrane receptors 
such as receptor activity modifying proteins, other membrane proteins, or other intracellular 
molecules (2,6))RUH[DPSOHIROORZLQJSKRVSKRU\ODWLRQRIWKHUHFHSWRUȕ-arrestin molecules (an 
adaptor molecule involved in receptor internalization) bound to the GPCR may link the receptor to 
Src-kinase activation and subsequent activation of components in the mitogen-activated protein 
kinase (MAPK) pathway (15). Similarly, several GPCRs have been shown to complex with small 
GTP-binding proteins such as Ras, Rab, and Rho, leading to activation of phospholipase D (16). 
 GPCRs are now understood to mediate a multitude of interconnected signalling pathways, 
with the final outcome a composite product of the various G proteins and signal transduction 
SDWKZD\V DFWLYDWHG DW DQ\ RQH WLPH $V VXFK WKHUH KDYH EHHQ YDOLG DUJXPHQWV WKDW WKH WHUP ³*
protein-FRXSOHGUHFHSWRU´LVQRORQJHUDSSURSULDWHDQGWKDWWKHGHVLJQDWLRQ³VHYHQ-transmembrane 
UHFHSWRU´RU³KHSWDKHOLFDOUHFHSWRU´EHSUHIHUDEO\XVHG (16). 
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1.1.3 GPCRs: An area of continued interest in drug discovery 
The fact that the GPCRs are so varied has made them one of the top targets in drug discovery and 
development today, with an estimated 30% of the pharmaceuticals available on the market targeting 
them (17). Table 1-1 depicts some examples of successful pharmaceuticals targeting the GPCRs. 
Despite this large market share, these drugs currently target only approximately 30 GPCRs, with a 
large contribution from the rhodopsin family, particularly the biogenic amine receptors (17). 
Therefore, the remaining known GPCRs within the superfamily, together with the orphan receptors, 
represent a vast amount of untapped potential for future pharmaceutical research and development, 
although it should be noted not all GPCRs may play a pathological or targetable role in disease 
states.  
 
Trade Name 
(Generic name) 
GPCR targeted Indication Company 
Plavix® 
(Clopidogrel) 
Purinergic P2Y12 Myocardial infarction Sanofi-Aventis 
Zyprexa® 
(Olanzapine) 
Serotonin 5HT2, Dopamine 
D1,D2, D4 
Muscarinic M1, 
$GUHQHUJLFĮ 
Histamine H1 
Schizophrenia, bipolar 
disorder 
Eli Lilly 
Diovan® 
(Valsartan) 
Angiotensin AT2 Hypertension, heart failure, 
post myocardial infarction 
Novartis 
Serevent® 
(Salmeterol) 
Adrenergic ȕ2 Asthma GlaxoSmithKline 
Oxycontin® 
(Oxycodone) 
2SLRLGț Pain Purdue Pharma 
Singulair® 
(Montelukast) 
Cysteinyl leukotriene 
CysLT1 
Asthma Merck 
Clarityn® 
(Loratadine) 
Histamine H1 Allergic rhinitis Schering-Plough 
Table 1-1 Examples of marketed drugs targeting GPCRs. 
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1.1.4 Pharmacological assays for GPCRs  
Research efforts involving GPCRs primarily focus on the discovery of novel ligands as leads for the 
development of potential therapeutic compounds. Novel ligands are typically assessed in vitro for 
binding affinity and efficacy using cell lines stably transfected with the receptor of interest. Binding 
affinity (Ki) is frequently determined using a competition binding assay with a known radiolabelled 
ligand. Functional activity (i.e. whether a ligand is an agonist, neutral antagonist, or inverse agonist) 
can be determined using a variety of functional assays that measure either GTP, cAMP or IP3 levels 
using radiometric, luminescence or fluorescence techniques (18).  
Most GPCRs typically possess some degree of constitutive activity (a basal level of 
activation in the absence of any agonist) due to a proportion of the receptors being in an activated 
state. Full agonists induce the maximal level of activation possible, partial agonists activate the 
receptor above basal levels but not maximally, neutral antagonists bind to the receptor but 
maintains basal levels by neither stimulating nor inhibiting the receptor, while inverse agonists 
decrease the level of receptor activation below basal levels (19). 
 
Figure 1-3 Pharmacological effect of agonists, partial agonists, neutral antagonists and inverse 
agonists. Taken from reference (19). 
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As the [356@*73Ȗ6binding assay is employed for the purposes of this thesis, only this particular 
method is discussed here. 
 
1.1.4.1 Competition binding assays 
Competition binding assays using a radioligand allow the binding affinities of unlabelled 
compounds to be determined by measuring their ability to displace a fixed concentration of known 
radiolabelled ligand from the receptor (20). As the level of radioactivity detected is directly 
proportional to the amount of radioligand that remains bound to the receptor, measurement over a 
logarithmic range of competing ligand concentrations allow for the plotting of inhibition curves 
using non-linear regression. The inhibition constant (IC50) from the assay, which is defined as the 
concentration of ligand that inhibits the binding of the radioligand by 50% and is experiment 
specific, can then be converted into binding affinity (Ki) using the Cheng-Prusoff equation (21): ܭ௜ ൌ ହ଴ ? ൅  ሾሿ௄ ? 
Equation 1 The Cheng Prusoff equation. Where Ki is the binding affinity of the ligand, IC50 is the 
experimentally determined inhibition constant, [L] is the radioligand concentration and Kd is the 
dissociation constant of the radioligand. 
&RPSHWLWLRQ ELQGLQJ DVVD\V KRZHYHU SURYLGH QR LQIRUPDWLRQ RQ WKH ELQGLQJ OLJDQG¶V IXQFWLRQDO
activity, and other methods must be employed to determine if the ligand is an agonist, neutral 
antagonist or inverse agonist.   
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 1.1.4.1  [356@*73Ȗ6ELQGLQJDVVD\ 
The [356@*73Ȗ6 ELQGLQJ DVVD\ DOORZV IRU WKH GHWHUPLQDWLRQ RI D OLJDQG¶V HIILFDF\ DW *3&5V E\
measuring the enhancement of GTP binding upon receptor activation (22). [356@*73Ȗ6 LV D
radiolabelled, non-hydrolyzable analogue of GTP. Upon receptor activation [356@*73Ȗ6DVVRFLDWHV
ZLWK *Į VXEXQLW RI WKH * SURWHLQ DQG Ds it cannot be hydrolysed back to GDP,  the G protein 
heterotrimeU FDQQRW UHIRUP UHVXOWLQJ LQ DQ DFFXPXODWLRQ RI *Į subunits. Measurement of the 
directly proportional radioactivity allows the % of receptor activation to be calculated; dose 
response curves can then be plotted in order to determine EC50 values. As this assay measures the 
event directly resultant from ligand-receptor binding, it has an advantage over functional assays 
which measure other downstream events, such as measurement of intracellular cAMP levels or 
MAPK phosphorylation, in that it minimizes the effect of signal amplification and interference 
from other signalling pathways.  
Results from [356@*73Ȗ6ELQGLQJDVVD\V  are typically expressed as a percentage of basal 
binding, with agonists showing a % basal binding over 100%, neutral antagonists showing 
negligible change in binding, and inverse agonists showing a % basal binding below 100%. 
Alternatively, results can be expressed as a percentage of the maximum response achieved by a 
known full agonist under identical conditions, which has the added advantage of providing a clearer 
indication of the level of agonist activation achieved. In this case full agonists show a response 
close to 100%, neutral antagonists show a response of 0%, while inverse agonists show a response 
below 0%. 
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1.1.5 Challenges in X-ray crystallography of GPCRs 
With the continued interest in the GPCRs by both academic and industrial researchers, there has 
been a need for the three-dimensional structures of these proteins to be elucidated for use in 
structure-based drug design, virtual screening projects and in studying their structure-function 
relationships.  However, like most membrane proteins, there are several inherent challenges that 
must be overcome when attempting to crystallize GPCRs for X-ray diffraction (19,23), a typical 
method of obtaining 3D structures of proteins. In fact, the first crystal structure of a mammalian 
GPCR, that of bovine rhodopsin, was only solved in the year 2000 (24). 
Firstly, GPCRs are generally expressed at low levels in native cells (a notable exception 
being bovine rhodopsin, which is highly expressed in rod cell disc membranes) (23,25). 
Recombinant systems developed must therefore be capable of high expression levels and native 
protein folding (23). Secondly, GPCRs have poor thermodynamic stability during the purification 
process, and are also prone to proteolysis due to their flexible extramembranous regions (23). 
Thermodynamic stability has been achieved by methods such as utilizing stabilizing ligands, 
stabilizing mutations, high salt concentrations, and the addition of lipids during the purification and 
crystallization process (26±29). Receptor stability and  structure resolution has also been enhanced 
by truncating disordered regions, engineering disulfide bonds between loops, receptor-antibody Fab 
fragment complex formation, fusion of T4-lysozyme (T4L) with the receptor, and the utilization of 
nanobodies (26±28,30). Thirdly, once the GPCRs are detergent-solubilized, there are difficulties in 
growing diffraction quality crystals, owing to their flexible third intracellular loop and C terminus, 
as well the fact that they lack a considerable exposed polar surface area in order to form crystal 
lattice contacts (27). The methods developed involving T4L fusion and antibody Fab complexes 
addressed these issues, stabilizing the receptor and providing the contacts needed for 
crystallogenesis (26,27,30). Both these approaches also relied on advances in lipid-mediated 
crystallogenesis, such as bicelle crystallization and lipid mesophase techniques (31,32). 
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 As a result of these new techniques, the crystal structures of GPCRs other than bovine 
rhodopsin have been solved in recent years, including those of the DGUHQHUJLFȕ1 and ȕ2  in 2007, 
adenosine A2A in 2008, dopamine D3 in 2010, chemokine CXCR4 in 2010, histamine H1 in 2011, 
nociceptin receptor NOP in 2012, opioid ț ȝ DQG į in 2012, muscarinic M2 and M3 in 2012, 
neurotensin 1 receptors in 2012, protease-activated receptor PAR1 in 2012, sphingosine-1 
phosphate S1P1 in 2012, corticotrophin-releasing factor receptor 1 CRF1 in 2013, and glucagon 
receptor GCG in 2013 (26,28,29,33±45). In addition, the ȕ2 receptor in complex with the Gs 
protein has also recently been crystalized, representing a major breakthrough in the crystallography 
of GPCRs (46).  These structures, however, still only represent a minute portion of the GPCRs. Due 
to the costs and time involved in elucidating GPCR structures via X-ray diffraction, coupled with 
the possibility that techniques such T4L fusion may possibly introduce structural artefacts, protein 
structure prediction and other computational methods are proving to be a valuable method of 
producing three-dimensional structures for studying the GPCRs.  
 
1.1.6 GPCR amino acid numbering system 
All amino acid residues in GPCRs presented in this thesis are numbered using the system presented 
by Ballesteros and Weinstein (47). According to this system, each amino acid number begins with 
the TM helix number in which the amino acid is located, followed by a locant. The most highly 
conserved residue within that helix is arbitrarily assigned a locant of 50. For example, the most 
highly conserved residue in TM3 of GPCRs is the arginine in the DRY motif. Consequently, using 
the Ballesteros-Weinstein system, this arginine is numbered as R3.50, is preceded by D3.49, and 
followed by Y3.51. Residues located within the extra and intracellular loops are numbered using 
their global position within the protein amino acid sequence. 
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Figure 1-4 Ballesteros Weinstein numbering in GPCRs. Taken from reference (48). 
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1.2  The cannabinoid receptors CB1 and CB2 
1.2.1 Discovery, distribution and classification
 
Cannabis, also colloquially known as marijuana, hashish or weed, is the name given for 
preparations derived from the plant Cannabis sativa and is one of the most popular illicit drugs 
used recreationally today, mainly due to its euphoric effects and the ability to alter sensory 
perception (49).  Despite being classified as a substance of abuse in many countries, the diverse 
properties of this plant on human physiology have been utilized therapeutically for several 
millennia and are well documented (50).  
The bioactive constituents of cannabis, which are lipophilic, were originally thought to act 
non-specifically via the perturbation of lipids in the cell membrane (51). However, the elucidation 
of the structure of delta-9-tetrahydrocannabinol 1 (¨9-THC) (see Figure 1-5), the main psychoactive 
constituent of cannabis, whose structure was subsequently used to define the classical cannabinoids, 
and further studies demonstrating its stereo-selectivity and structural-selectivity led to the view that 
a distinct receptor existed for ¨9-THC (52±54). The demonstration of the existence of a saturable, 
high-affinity stereospecific binding site in the brain of mice for [3H]CP55940 3 (a synthetic, non-
classical cannabinoid) by Devane et al in 1988 provided definite evidence of the existence of this 
then unknown receptor (55). Further research in this area finally led to the identification of an 
orphan GPCR in the brain that bound the cannabinoids, and this GPCR was subsequently termed 
cannabinoid receptor CB1 (56). While being most abundant in the human brain, CB1 receptors 
have since been shown to also be present in peripheral, metabolically-relevant tissues such as liver, 
skeletal muscle, adipose tissue, and pancreas, albeit at lower concentrations (57±60). This was 
subsequently followed by the identification of a second cannabinoid receptor, termed CB2, which is 
expressed mainly in the cells of the immune and haematopoetic systems, but is also found in the 
brain, adipose tissue, skeletal muscle, and pancreas (58,61±63). In recent years there have been 
22 
 
pharmacological studies suggesting the existence of a third cannabinoid receptor, among the 
possible candidates being the orphan receptor GPR55, although this view is controversial, and 
based on current evidence, no receptor other than CB1
 
and CB2 fits all the criteria to be classified 
as a novel cannabinoid receptor (64). 
 
 
Figure 1-5 Selected cannabinoid receptor ligands. $ &ODVVLFDO FDQQDELQRLGV ǻ9 ±THC and 
HU210. (B) Non-classical cannabinoid CP55940. (C) Aminoakylindole agonist WIN5521202. (D) 
Endogenous cannabinoids anandamide and 2-AG. (E) CB1
 
selective antagonist SR141716A. (F) 
CB2 selective antagonist SR144528 
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In Fredriksson et al¶V paper, the CB1 and CB2
 
 receptors are classified as belonging to the 
Į-group in the rhodopsin family of GPCRs, putting them in the same receptor cluster as the 
melanocortin receptors, endothelial differentiation GPCRs, and adenosine receptors (1). 
Interestingly, the CB1 and CB2
 
 receptors themselves only show 44% sequence homology between 
themselves overall, with this figure rising to 68% if only the transmembrane regions are taken into 
account (61). 
 
1.2.2 Endogenous cannabinoids 
Simultaneous with the discovery of the cannabinoid receptors, proof of the existence of an 
endogenous ligand was provided following the isolation of anandamide from porcine brain tissue 
(65). Anandamide 5 has been shown to be a CB1 selective ligand, where it displays partial or full 
agonist activity (66). Anandamide is mainly synthesized in vivo from the membrane lipid precursor 
N-arachidonoylphosphatidylethanolamide (NAPE) utilizing a pathway involving phospholipase D, 
and degraded by fatty acid amide hydrolase (FAAH), though other parallel pathways may exist 
(67,68). The isolation of anandamide was followed by the discovery of 2-arachidonoylglycerol 6 
(2-AG), the second endocannabinoid. 2-AG is synthesized in vivo from diacylglycerol (DAG) via 
the enzyme DAG lipase (69,70). While anandamide and 2-AG represent the endocannabinoids 
predominantly present in the brain, several other endocannabinoids of the eicosanoid class have 
also been shown to exist, namely 2-arachidonoyl glycerol ether, O-arachidonoylethanolamie 
(virodhamine), and N-arachidonoyl dopamine (71±74). These lipid-derived, highly lipophilic 
ligands, were found to be structurally distinct from the first cannabinoid ligands described, which 
were mainly synthetic analogues that followed the discovery of ¨9-THC (such as the classical 
cannabinoid HU210 2, non-classical cannabinoid CP55940 3, and the aminoakylindole WIN 
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55212-2 4), an early indicator of the diversity of ligands capable of binding to the cannabinoid 
receptors. 
 
1.2.3 Cannabinoid receptor signalling 
As expected of GPCRs, signal transduction of the cannabinoid receptors is complex but occurs 
mainly through G proteins, specifically the Gi subtype (75). As such, activation of the cannabinoid 
receptors leads to an inhibition of adenylyl cyclase and a decrease in cellular cAMP levels in a 
pertussis toxin-sensitive manner. Some studies have also shown the cannabinoid receptors to be 
capable of stimulating cAMP production to some degree, with proposed mechanisms for this 
activity including production of another endogenous activator of adenylyl cyclase such as 
prostaglandin, augmentation of Gs activity and activation of isoforms 2/4/7 of adenylyl cyclase via 
*ȕȖ GLPHUV XQFRXSOHG IURP *i and direct interaction with Gs (76±81). Additionally, the 
cannabinoid receptors have been shown to signal through many of the non-G protein pathways 
described earlier that will not be discussed here, but is subject to a review by A.C Howlett (82). 
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1.2.4 Therapeutic potential of targeting the cannabinoid receptors 
The cannabinoid receptors and their distribution throughout the human body result in their 
contribution in the regulation of a variety of physiological processes as well as the pathology of 
many disease states. As such, over the years in vitro assays, animal studies and clinical trials have 
highlighted a multitude of pathophysiological conditions where pharmacotherapy targeting either 
one or both cannabinoid receptors may potentially be of benefit. These diseases include: 
x Obesity and other related metabolic disorders 
x Anorexia and cachexia 
x Pain and inflammation 
x Stroke and neurotoxicity 
x Multiple sclerosis 
x 0RYHPHQW GLVRUGHUV VXFK DV 3DUNLQVRQ¶V GLVHDVH GUXJ-LQGXFHG G\VNLQHVLD +XQWLQJWRQ¶V
GLVHDVH7RXUHWWH¶VV\QGURPHDQGWDUGLYHG\VNLQHVLD 
x $O]KHLPHU¶VGLVHDVH 
x Amyotrophic lateral sclerosis 
x Epilepsy 
x Anxiety and depression 
x Schizophrenia 
x Insomnia 
x Drug or alcohol addiction 
x Nausea and emesis 
x Cardiovascular diseases such as hypertension, atherosclerosis, myocardial reperfusion 
injury, and circulatory shock 
x Asthma 
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x Glaucoma and retinopathy 
x Cancer 
x Hepatitis and liver cirrhosis 
x Inflammatory bowel disease 
x Arthritis 
x Osteoporosis 
 
 It is clear from the length of this list that pharmacological modulation of the 
endocannabinoid system possesses substantial therapeutic potential. As a full discussion regarding 
all the diseases listed is beyond the scope of this thesis, the focus here will be on conditions in 
which drugs targeting the cannabinoid receptors have successfully entered Phase III clinical trials or 
gained regulatory approval. Readers who are interested in obtaining more information on the role of 
cannabinoids in all of the conditions listed are directed to an excellent review by Pacher et al (83), 
from which the above list is derived. 
 
1.2.4.1 Obesity and related metabolic disorders 
It has been known for many years that the use of cannabis increases appetite and can cause 
significant weight gain, and following further study the orexigenic (i.e. appetite stimulating) 
properties of ¨9-THC was experimentally demonstrated (84). As such, the role of the 
endocannabinoid system in regulating appetite centrally and via peripheral energy metabolism has 
been a main focus of research over the years. Studies have revealed that the endocannabinoid 
system modulates feeding centrally through decreasing satiety signals, enhancing orexigenic 
signals, as well as increasing eating motivation through reward mechanisms involving the 
mesolimbic pathway (reviewed in (85) and (86)). Peripherally, the endocannabinoid system 
modulates energy expenditure, and it has been shown that CB1 knockout mice are resistant to 
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obesity induced by diet and have increased energy expenditure (59,87). Treatment of diet-induced 
obese mice with the CB1 inverse agonist SR141716A 7 (rimonabant) showed a reduction in food 
intake that was transitionary in nature (suggesting tolerance to the central effects of rimonabant), 
but a reduction in body weight that was sustained, highlighting the importance of increased 
peripheral energy expenditure in the response (88). As overactivity of the endocannabinoid system 
has been implicated in clinical obesity, with obese patients showing elevated endocannabinoid 
levels in the adipose tissues, it followed that treatment with a CB1
 
antagonist/inverse agonist had 
potential clinical benefit (89). Consequently, rimonabant was further developed by Sanofi-Aventis 
as an anti-obesity agent under the trade name Acomplia®.  
 Four clinical trials involving rimonabant, known as the RIO (Rimonabant In Obesity) trials, 
showed that administration of rimonabant was associated with a reduction in body weight that was 
sustained as long as treatment was continued, decreased plasma glucose and insulin levels, as well 
as improvements in the lipid profiles of patients as demonstrated by a decrease in plasma 
triglycerides and an increase in high-density lipoprotein (HDL) cholesterol levels (90±93). 
Following these trials the European Medicines Agency (EMEA) approved Acomplia® in 2006 for 
the treatment of overweight and obese patients, defined as patients with Body Mass Index > 
27kg/m2, who have associated risk factors such as type 2 diabetes and dyslipidaemia. 
 Unfortunately, rimonabant failed to gain regulatory approval from the U.S Food and Drug 
Administration (FDA), due to concerns over psychiatric adverse events associated with its use that 
were inadequately highlighted in the RIO trials, such as depression, agitation, anxiety, seizures, and 
suicidal ideation (94). Post-marketing safety data led to the EMEA voicing the same concerns, and 
sales of Acomplia® were suspended in October 2008, with approval of rimonabant finally 
withdrawn in January 2009 (95). The fallout of this incident led to discontinuation of several other 
CB1
 
antagonists/inverse agonists in clinical research, such as SR147778 9 (surinabant), MK0364 10 
(taranabant), and CP945598 11 (otenabant) (Figure 1-6).  
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Figure 1-6 Selective CB1 inverse agonists whose development have been discontinued 
 While CB1 antagonists/inverse agonists have failed to succeed as anti-obesity agents, the 
cannabinoid receptor agonist ¨9-THC (dronabinol) has been licensed as an appetite stimulant in 
AIDS patients, and is marketed as Marinol®. 
 
1.2.4.2 Chemotherapy-induced nausea and vomiting 
Chemotherapy-induced nausea and vomiting (CINV) is one of the most prevalent side-effects of 
current cancer-treatment regimens, and also one of the most debilitating. The pathophysiology of 
emesis is complex, involving multiple neurotransmitters in the gut and chemoreceptor trigger zone 
at the base of the brain (96) 7KH SKDUPDFRORJLFDO PHFKDQLVP RI FDQQDELQRLGV¶ anti-emetic 
properties are still unclear, but is hypothesized to possibly include an interaction with 5-HT3 
receptors (one of the most prominent receptors implicated in emesis) on GABAergic neurons, 
where they mediate opposing effects on GABA release (97). There is also evidence that CB1 
receptors located in the brainstem region control the vomiting reflex, while endocannabinoids in the 
gastrointestinal tract have a physiological role in emesis (98). Several small studies and case reports 
over the years have established the place of cannabinoids as a valuable option in CINV and 
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palliative care. A meta-analysis of 30 of these studies conducted by Tramer et al, with a total 
sample size of 1366 patients, concluded that the cannabinoids were slightly more effective than 
conventional anti-emetics, with higher patient preference due to their euphoric and sedating 
properties (99). However, the associated psychiatric adverse effects would limit their use as a first 
line agent.  
 As such, dronabinol and other cannabinoids have over the years gained acceptance as an 
anti-emetic in CINV, particularly when first line agents are inefficacious. Dronabinol (Marinol®), 
its synthetic analogue nabilone 12 (Cesamet®), and Sativex®, a cannabis-based preparation 
FRQVLVWLQJRIHTXDODPRXQWVRI¨9-THC and cannabidiol 13 (a non-psychoactive plant cannabinoid), 
have all been licensed for the suppression of nausea and vomiting associated with chemotherapy. 
 
Figure 1-7 Structures of nabilone and cannabidiol 
 
1.2.4.3 Multiple sclerosis and neuropathic pain 
Multiple sclerosis (MS) is an autoimmune, inflammatory disease which results in loss of the myelin 
sheath of neurons in the central nervous system, leading to a range of clinical symptoms that 
include painful muscle spasms, ataxia, paralysis, cognitive impairment, visual disturbances, 
incontinence, and constipation (100,101). Due to the complex nature of the neuronal system, 
symptoms frequently vary, relapse and remit. In particular, muscle spasticity and neuropathic pain 
constantly lead to reduced mobility, patient distress, and a reduction in quality of life (101). Drugs 
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targeting the immune system in order to slow progression of the disease remain moderately 
effective at best, and treatment tends to be primarily symptomatic (102). 
 Early animal models designed to mimic the pathology of MS have found that 
administration of cannabinoid receptor agonists such as ǻ9-THC, WIN 55212-2, JWH-133 14 and 
methanandamide 15 reduced muscle spasticity and tremor, whereas cannabinoid receptor 
antagonists exacerbated these symptoms (103). A possible explanation for these findings was 
offered when it was found that the endocannabinoid system is highly activated in MS patients, 
suggesting an autoprotective role of the endocannabinoids via a negative feedback loop (104). 
 
Figure 1-8 Structures of JWH-133 and methanandamide 
 
 Subsequently, cannabis extracts began to be the subject of studies involving MS patients, 
although most of these studies had extremely small sample sizes due to the rarity of the disease. 
However, one large multi-centre study involving 660 patients, found that after 15 weeks, treatment 
of MS patients with cannabinoids resulted in no change in Ashworth scores (a score measuring 
muscle spasticity), tremor, depression, or tiredness (105). On the other hand, significant 
improvements were found in patient-reported pain, spasticity and sleep quality. Interestingly, the 
treatment group also showed a reduction in hospital admissions for relapse. A 12-month follow up 
showed more promising results, with the treatment group showing marked improvements in 
Ashworth scores (106). A meta-analysis conducted in 2007 by Iskedjian et al supported these 
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findings, concluding that cannabis based treatments were effective in neuropathic and multiple-
sclerosis related pain (107). 
 Sativex® has since been licensed for the symptomatic treatment of neuropathic pain 
associated with multiple sclerosis and as an adjunctive analgesic in cancer patients (108). Trials 
studying the use of cannabinoids for the treatment of pain in other conditions are ongoing. 
 
1.2.5 Emerging strategies in targeting the cannabinoid receptors 
The lessons learnt in the marketing authorization withdrawal of rimonabant have led to proposed 
solutions to circumvent the psychiatric adverse events mediated by CB1
 
receptors in the central 
nervous system (CNS). Among the possible alternatives, as discussed in a review by R.G Pertwee, 
are developing neutral antagonists, developing peripherally-restricted ligands that are incapable of 
crossing the blood brain barrier, selective targeting of the CB2 receptors, targeting particular tissues 
expressing the cannabinoid receptors, targeting up-regulated receptors, and exploiting the ability of 
the endocannabinoid system to interact synergistically with other receptors and ligands (108). 
Several of these strategies could potentially be achieved by the rational design of novel cannabinoid 
receptor ligands. 
 The development of a neutral antagonist would likely allow for the beneficial effects of 
CB1 blockade without compromising central constitutive activity, thus theoretically allowing for a 
reduction in psychiatric adverse effects. In a similar manner, the development of ligands that retain 
potency and are less lipophilic, and thus unable to cross the blood-brain barrier, would achieve the 
same result. Indeed, preclinical evidence demonstrating the viability of this approach has already 
been presented by Dziadulewicz et al, who developed a potent, orally bioavailable, cannabinoid 
receptor agonist that was capable of producing analgesic activity with limited CNS penetration in 
animal models of neuropathic pain (109). 
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 Currently, none of the CB2 selective agonists available are entirely CB2-specific, and only 
show selectivity within a finite dose range (108). Agonists of the CB2 receptor have also been 
shown to display analgesic activity in many models of acute, neuropathic, inflammatory, cancer-
related, and post-operative pain (reviewed in reference (110) and (111)). It has been demonstrated 
that CB2-selective agonists are capable of producing these anti-nociceptive effects at doses that do 
not result in observable central CB1-related effects (110,111). While other factors, such as the CB1 
to CB2 receptor expression ratio may affect the dose required to achieve this effect, the 
development of highly selective CB2 agonists would significantly improve the range of this 
therapeutic window (108). The development of novel CB2-selective agonists has been a focal point 
of research in recent years, with new scaffolds based on 4-oxo-1,4-dihydroquinoline-3-carboxamide 
(112), 1,8-napththyridine-4(1H)-one-3-carboxamide (113,114), 4-quinolone-3-carboxylic acid 
(115), and oxazinoquinolone motifs (116,117) being described. While some of these relatively new 
compounds have shown promise, such as GW842166X 16 which is currently in clinical 
development for the treatment of inflammatory pain (118), there is still a need for novel leads 
targeting the cannabinoid receptors.   
 
Figure 1-9 Structure of GW842166X 
 The ability of cannabinoid receptor ligands to interact with other receptors, such as the 
vanniloid TRPV1 receptor, may also be potentially exploited therapeutically via the development of 
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a single ligand that targets both receptors. One such ligand, which acts as both a CB2 receptor 
inverse agonist and a TRPV1 receptor agonist, has already been developed, and has been proposed 
to possess potential anti-inflammatory activity (119) 7KH SODQW FDQQDELQRLG ¨9-
tetrahydrocannabivarin has also been shown to simultaneously activate CB2 receptors and block 
CB1 receptors, a combination that could be beneficial in the treatment of stroke and chronic liver 
diseases (108,120). Other receptors, such as the peroxisome proliferator-activated receptors (PPAR) 
have also been shown to be activated by anandamide (121). These examples thus highlight the 
potential of the development of cannabinoid ligands that affect multiple targets. 
 These strategies emphasize the unmet need for novel compounds targeting the cannabinoid 
receptors. A better understanding of the cannabinoid receptors, their structure-function 
relationships, their interaction with ligands, and the principles which govern receptor selectivity 
would therefore allow for the rational design of ligands capable of achieving the above. 
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1.3 Molecular modelling of the cannabinoid receptors 
To date, the crystal structure of both cannabinoid receptors remains unsolved. As such, over the 
years numerous homology models of the cannabinoid receptors have been used in order to study 
these receptors at an atomistic level. This chapter serves to highlight some of the many successful 
applications of molecular modelling of the cannabinoid receptors, beginning with a discussion on 
the key concepts of molecular modelling techniques.  
 
1.3.1 Key concepts in molecular modelling 
1.3.1.1 Homology modelling 
The three-dimensional structures of proteins are traditionally deduced experimentally using 
spectroscopic methods such as NMR and X-ray crystallography before being deposited in 
repositories such as the Protein Data Bank (PDB) (122). As of August 2013, the PDB contained 
approximately 86,000 protein structures, although the actual number of unique protein structures is 
much lower as the PBD contains multiple entries for the same protein determined under differing 
conditions and resolutions. The gap between the number of unique protein sequences known and 
structures solved continues to widen however, due to the disproportionate resources and time 
required for each task; the generation of diffraction-quality crystals of certain proteins (particularly 
membrane proteins) remains the primary bottleneck in the structure-elucidation process (123). As 
such, various computational methods allowing for the prediction of 3D models of proteins for 
which experimental structures are absent have in recent years become invaluable in bridging this 
gap, with such structure prediction methods being collectively known as homology modelling. 
 Homology modelling can be defined at an elementary level as the prediction of the three-
dimensional structure of a protein for which its sequence but not structure is known, using its 
alignment to a homologous (related) protein whose structure has been experimentally determined 
(124). While various methods for the homology modelling of a particular target exist, the general 
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principles and processes remain similar: a suitable template is selected, an alignment between target 
and template is determined, an initial model is constructed, the model is refined and validated, and 
the process is reiterated until an acceptable model is generated. 
 
 
Figure 1-10 General process of homology modelling. 
 The selection of a suitable structural template is typically done by utilizing specific 
sequence alignment algorithms such as BLAST (125) or PSI-BLAST (126) to search databases 
such as the PDB for structures which are related in sequence to the target protein. If the protein 
family of the target is already known (e.g. if the target is known to be a GPCR), the field of search 
can be narrowed down substantially by performing sequence alignments only against structures in 
the same protein family to find the template with the highest sequence identity to the target, though 
other factors such as the X-ray resolution may play a role in template selection. The use of multiple 
templates may also be beneficial in cases of low sequence identity, though this effect is primarily 
due only to an improvement in the sequence alignment between target and template (127). 
 Following the identification of a suitable template or templates, most sequence alignments 
produced during the initial screen will require some form of refinement. Sequence alignment 
remains the one of the most crucial steps in homology modelling as any error in alignment would 
be subsequently amplified. The chance of such errors can be minimized via the utilization of 
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multiple sequence alignments and a knowledge-based approach when refining the initial alignment. 
Multiple sequence alignments allow for the delineation of strongly divergent areas in the sequences, 
where mutations resulting in amino acid insertions and deletions are more likely to occur. If the 
general fold of the protein family is known, areas where gaps in the sequence alignment are less 
likely to occur may have been previously identified, for example in the hydrophobic core of 
transmembrane proteins, and such information may be used to manually improve any algorithm-
generated alignment. 
 An initial model can then be constructed using this alignment, and while various programs 
exist for this task models are generally constructed in the same manner; residues in the template are 
replaced by the target residues using the same protein backbone coordinates, with only the side 
chains being varied. The model is then refined to minimize any high energy clashes that may have 
been generated in this process. At this stage the model is normally checked for structural integrity 
via visual inspection and comparison with known crystal structures through methods such as 
Ramachandran plots, which compares thH DPLGH ERQG ĳ DQG ȥ DQJOHV RI WKH model against 118 
proteins with known crystal structures of resolution 2.0 Å or better (128,129). An example of a 
Ramachandran plot is shown in Figure 1-11.  
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Figure 1-11 A typical Ramachandran plot. The contours on the plot were derived from the ĳ 
and ȥ angles of 118 protein crystal structures. The red, yellow, beige, and white regions 
represent the most favoured, additionally allowed, generously allowed and disallowed 
regions respectively.  
The precise backbone conformation, side chain rotamers, and hydrogen-bonding networks 
in this initial model are however, broadly similar to the template and likely inaccurate. While there 
are many more paths leading away from the desired target state than towards it, in recent years 
models typically undergo refinement and optimization using various methods, the most prominent 
of which are molecular dynamics and Monte Carlo simulations due to increasing force field 
accuracy, sampling efficiency, and computational capability (124,130,131).  
 The refined model can then be validated or evaluated based on its intended use, usually via 
the reproduction of known experimental data. In typical drug discovery applications, the model may 
be evaluated through docking and predicting the binding affinities and interactions of known 
ligands, or used to screen a virtual library of known ligands and decoy molecules in order to obtain 
an enrichment factor or Receiver Operating Characteristic (ROC) curve, which measures the ability 
of a particular virtual screening protocol to select active compounds when compared to random 
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screening (132). ROC curves have several advantages over conventional enrichment curves (which 
plot the fraction of actives found against the fraction of database screened), one in particular is that 
they are independent of the rate of active molecules in the sample set (133).  If the evaluated model 
is unable to produce the desired outcome, the process can be reiterated; with a different model 
selected and the evaluated until a satisfactory model that is deemed to be representative of the target 
is obtained. 
  
1.3.1.2 Molecular dynamics and empirical force fields 
Three-dimensional models of a protein obtained through either crystallographic techniques or 
homology modelling can provide useful information regarding its structure. However, these static 
representations merely represent one possible conformation of an ensemble, as proteins in real 
biological systems are dynamic in nature (134). Homology models, particularly those with low 
sequence identities, may also be in non-native conformations that are similar to their templates, 
necessitating refinement. Molecular dynamics (MD) represents one of the most prominent methods 
in computer simulations of biological macromolecules to address these issues, allowing for the 
study of a wide range of system properties and behaviour based on the principle that these 
properties can all be derived from the interactions between atoms in the studied system (135).  
 MD simulations generate successive configurations of a system by solviQJ 1HZWRQ¶V
equations of motion (135). By taking into account the interaction energy between all atoms in the 
system, the force acting on each individual atom is derived, and their new coordinates after a fixed 
time step (typically 1 or 2fs) is calculated. This process is repeated several million times in order to 
generate a trajectory from which system properties and behaviour can be studied. In the context of a 
receptor-ligand system, these trajectories can be used to sample receptor conformations, deduce key 
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amino acid residues, investigate ligand binding and approximate ligand binding affinity via the 
derivation of the free energy of binding, as well as to probe receptor activation mechanisms.  
 The interactions between all the atoms in a system, and correspondingly the forces they 
experience at each successive time step, are governed by a pre-defined set of equations known as a 
force field (136). These empirical (electronic effects are ignored and interactions are calculated 
based only on nuclear positions) force fields typically have the following functional form:     
 
Equation 2 General form of an empirical force field 
Interactions are generally divided into bonded (bonds, angles and dihedrals) and non-bonded 
(electrostatic and Van der Waals) interactions. Bonded interactions such as bonds and angles are 
WUHDWHGDVVLPSOHVSULQJVJRYHUQHGE\+RRNH¶V/DZZKLOHGLKHGUDOVDUHJRYHrned by a sinusoidal 
function. Non-bonded interactions are modelled using a 12-6 Lennard-Jones potential for van der 
Waals interactions and a Coulombic potential for electrostatic interactions (137). Numerous force 
fields exist that differ mainly in the way these equations are parameterized and the experimental 
data in which they are validated against; well-known examples being the CHARMM, AMBER, and 
GROMOS force fields (138±140). 
 The scope of feasible simulations using MD is limited primarily by two factors, namely 
force field accuracy and computational demand (137). While force fields have been constantly 
refined over the past two decades to include different classes of molecules and validated using 
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various methods, there is still room for improvement, and the result of any simulation has to take 
into context known experimental data. The availability of computing power limits most simulations 
for large systems such as membrane proteins to several hundred nanoseconds, but many biological 
processes of interest such as receptor activation take place on the micro- to millisecond time scale, 
which is unachievable by most research groups that are without access to specialized 
supercomputers such as Anton (141).  
 
1.3.1.3 Automated docking 
In the context of virtual high throughput screening or structure-based drug design projects, the 
primary aim is typically to either identify potential leads from small molecule databases or to 
predict the binding mode of a particular class of ligands to its receptor. The large number of ligands 
to be processed in both cases necessitates a method that is computationally inexpensive without 
compromising prediction accuracy. Docking remains the primary method used to achieve these 
goals. 
 On a fundamental level, docking can be defined as a computational technique that is used 
to predict the binding conformation and binding affinity of a ligand to its receptor (135,142). When 
a series of ligands is docked successively, the ligands can be ranked according to their predicted 
binding affinities, allowing the identification of potential lead molecules. While the exact method 
may differ, most docking programs typically combine a search algorithm and a scoring function 
(see Figure 1-12). Using a representation of the receptor (derived from X-ray structures or 
homology models), the search algorithm first generates possible conformations of the ligand within 
a defined binding site. Methods for conformational sampling of the ligands vary from incremental 
construction to genetic algorithms and Monte Carlo methods, and normally incorporate biases or 
local search methods such that the attributes of energetically favourable conformations are kept in 
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successive conformations (142).   Each conformation is then scored based on the energetics 
between ligand and receptor, and the conformations ranked in order to provide a best prediction of 
the binding mode and binding affinity. 
 
Figure 1-12 General process of computational docking. 
 The challenges in computational docking are well documented, the most prominent of 
which involve current empirical scoring functions which are unable to account fully for entropic 
and solvation effects and may perform poorly in estimating exact binding affinities when evaluated 
over a large sample of diverse protein-ligand complexes (142,143). Various studies comparing 
current scoring functions have concluded in general that they perform better in identifying correct 
binding poses in protein-ligand complexes than estimating binding affinities, and that no one  single 
scoring function outperforms the others in all cases, though consensus scoring may be of some 
value (143±148). Other challenges such as the accuracy of the receptor model (particularly 
homology models) and the incorporation of receptor flexibility without increasing computational 
cost may further influence results, and thus hypotheses-driven approaches utilizing available 
experimental information about the target are invaluable in analysing the results of any docking 
study (142,149) 
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1.3.2 Molecular modelling studies of the cannabinoid receptors 
These studies are broadly divided into two categories: (i) primarily computational studies which are 
typically used to investigate receptor structure, deduce ligand binding, and for virtual screening, 
and (ii) studies complementing mutagenesis and pharmacological investigations. 
 
1.3.2.1 Computational studies elucidating receptor structure and ligand binding 
The first homology model of the cannabinoid receptors was described by Bramblett et al in 1995, 
where the authors used a variety of methods such as hydrophobic and variability moment vectors to 
identify the transmembrane helices of the CB1 receptor and delineate the orientation of each helix 
within the lipid membrane. A tentative helix bundle arrangement was then obtained that was 
consistent with the then-proposed helix arrangement of rhodopsin (150). Mahmoudian et al 
subsequently constructed a model of CB1 with the transmembrane helices based on the electron 
density map of bacteriorhodopsin, which is a seven-transmembrane protein but not a GPCR, and 
refined the model using energy minimization and molecular dynamics with the CHARMm 
forcefield. AUTODOCK was tKHQXVHGWRGRFN¨9-THC into this model and a binding site for this 
ligand was proposed (151). 
 Following the release of the crystal structure of bovine rhodopsin, Xie et al constructed a 
model of the CB2
 
receptor utilizing the aforementioned crystal structure as a template for the 
transmembrane regions (152). A multiple sequence alignment involving ten GPCRs was used, and 
the loop regions were generated by searching the Protein Data Bank (PDB) IRU KRPRORJRXV &Į
backbone sequences (122). Residue side chains were positioned using rotamer library searches, 
minimization and simulated annealing methods. This model was then used to identify helix tilt 
angles, conserved residues, hydrogen-bond networks, and potential disulfide bonds. 
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 Shim et al constructed a model of the CB1 receptor based on bovine rhodopsin in order to 
study the binding of several non-classical cannabinoid agonists (153). A docking method combining 
Monte Carlo and molecular dynamics simulations highlighted two possible binding conformations 
based on the placement of the ligand. The authors then proposed one conformation as being more 
probable, based on calculated binding energies and their correlation with experimental data, and 
proceeded to identify key interacting residues. 
 The high levels of constitutive activity of the CB1 receptor was studied by Singh et al, who 
following comparison of CB1 with rhodopsin, hypothesized that this was due to the lack of 
aromatic residues around the key residue W6.48 (154). Employing a biased Monte Carlo method 
known as Conformational Memories, the authors showed that W6.48 in CB1 had greater 
conformational flexibility, and that F3.36 helps constrain W6.48 in the inactive state, leading to the 
VXJJHVWLRQ RI D :) µWRJJOH VZLWFK¶ IRU FDQQDELQRLG UHFHSWRU DFWLYDWLRQ These findings 
were subsequently supported in a study by Latek et al, whose docking of agonists and antagonists to 
CB1 and CB2 models predicted binding in which the ligand type matched the state of this rotamer 
toggle switch; agonists changed the state of the switch while antagonists maintained it (155).  
 Utilizing these findings regarding this interaction and others involving WKHȕ
 
adrenoceptor, 
Tuccinardi et al modified inactive state models of the CB1 and CB2 receptors by adjusting the 
conformation of the toggle switch, rotating TM3 and TM6, and straightening TM6 (156). The 
UHVXOWDQWµDFWLYHVWDWH¶PRGHOV were subjected to docking analysis with the agonist WIN55212-2 in 
order to study CB2/CB1 selectivity. Further docking of several other ligands into the CB2
 
model 
produced a good correlation between experimental and estimated binding energies, confirming its 
reliability. This validated model was subsequently used by Durdagi et al to study conformations of 
the synthetic cannabinoid AMG3 17 in solution and in the binding pocket (157). A follow-up study, 
where homology models constructed using the ȕ2 adrenergic receptor were compared with the 
rhodopsin-based models, confirmed the ligand binding pocket that was previously derived (158). 
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Figure 1-13 Structure of synthetic cannabinoid AMG3 
 
 $QRWKHU VXFFHVVIXO H[DPSOH RI WKH PRGHOOLQJ RI DQ µDFWLYH VWDWH¶ FDQQDELQRLG UHFHSWRU
based on the modification of an inactive state model was shown by Renault et al (159).  By rotating 
the TM6 of their inactive state model, an active state model was produced following docking and 
MD with a known agonist. A 2D ligand-based Bayesian network was then computed to enrich a 
commercial library for virtual screening using their model and a consensus scoring approach. The 
selection of 150 compounds from the top 1% of the compounds screened resulted in 13 compounds 
showing good binding to the CB2 receptor in pharmacological assays, the majority of which 
behaved as agonists and included two novel full agonists. This select discovery of agonists 
demonstrated the validity of their active state model for the subsequent identification of key 
interactions in agonist binding. 
 While most homology models have focused on the TM region in which the majority of the 
key ligand interactions occur, Shim et al have previously examined the role of the second 
extracellular loop E2 in CB1 receptor ligand binding (160).  Using a combination of secondary 
structure prediction algorithms and molecular dynamics with simulated annealing, the authors 
determined the structures of E2 taking into consideration different oxidation states of two key 
cysteine residues within the loop. Distinct E2 structures were found to interact differently with the 
TM helices and had a significant effect on the binding site topology. The more biologically-relevant 
disulphide form of E2 was found to favour an agonist bound state, while the dithiol form favoured 
antagonist binding, revealing the possible significance of this loop in stabilizing receptor structure. 
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 One particularly ambitious study by Hurst et al sought to test the hypothesis that the 
endogenous cannabinoid 2-AG gains access to the binding site of the CB2
 
receptor via the lipid 
bilayer (161). To achieve this, the authors employed an all-atom molecular dynamics simulation of 
2-AG and the CB2 receptor embedded in a palmitoyl-oleoyl-phosphatidylcholine (POPC) lipid 
bilayer in the microsecond time scale. The resulting trajectories suggested that 2-AG is able to enter 
the receptor binding pocket by partitioning out of the bulk lipid and passing through the TM6/TM7 
interface. Following entry of the 2-AG headgroup into the binding pocket, the intracellular ionic 
lock between TM3 and TM6 is broken, leading to inter-helical motions that are associated with 
receptor activation. Subsequently, D3.49/D6.30 protonation and further ligand entry into the 
binding pocket results in a change in W6.48 toggle switch conformation and an influx of water. 
This elaborate study represented the first demonstration via molecular dynamics simulations of a 
ligand accessing the binding pocket of a GPCR via the lipid bilayer and triggering receptor 
activation.  
 More recently, Cichero et al combined typical homology modelling and docking methods 
with 3D-QSAR analyses to depict the agonist binding site of the CB2 receptor and guide design of a 
series of CB2-binding indol-3-yl-tetramethylcyclopropyl ketone derivatives (162). A theoretical 
PRGHO EDVHG RQ WKH ȕ2 adrenoceptor crystal structure was employed for the docking and MD of 
WIN55212-2 to identify key interactions for agonist binding. The subsequent docking of the novel 
class of agonists and Comparative Molecular Fields Analysis (CoMFA) and Comparative 
Molecular Similarity Indices Analysis (CoMSIA) resulted in a highly predictive model and the 
derivation of guidelines in the synthesis of indoles showing high CB2 affinity. 
 Taking into account that CB1 ligands are structurally diverse, Ai et al studied the 
hypothesis that the CB1 receptor may undergo significant conformational changes to accept 
different ligands (163). Four CB1 receptor models were constructed based on four distinct ligands 
(HU210, arachidonyl-2-chloroethylamide 18 (ACEA), WIN55212-2 and SR141716A) and two 
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FU\VWDO VWUXFWXUHV ȕ2 adrenoceptor and adenosine A2A). The models were optimized using 
molecular dynamics simulations, and were subjected to a docking analysis using known binders, 
structurally similar binders, and random compounds. Their results indicated that while each model 
was able to accept most CB1 ligands as the binding site remained similar, the key interactions 
derived from each model varied slightly according to the class of ligand the model was based upon. 
Thus, the authors concluded that models optimized for a particular ligand class may be more 
accurate in virtual screening. 
 
 
Figure 1-14 Structure of ACEA 
 
   1.3.2.2 Modelling studies complementing pharmacological data 
Homology models of the cannabinoid receptors are being increasingly used in conjunction with 
experimental mutagenesis data in order to form hypotheses regarding aspects of cannabinoid 
receptor function and ligand binding. In some studies, computational models of the cannabinoid 
receptors have been used to explain the findings of mutagenesis experiments in more detail. The 
reverse is also true, as computational models have also been used to highlight potential residues of 
interest for mutagenesis studies. 
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 Tao et al investigated the fact that mutation of the conserved lysine K3.28 in CB2
 
did not 
affect the binding of HU210 and CP55940 binding as in the CB1 receptor (164). Modelling of the 
CB2 receptor with CP55940 revealed an alternate binding mode that meant mutation of K3.28 did 
not affect ligand binding energy to a significant extent. Simultaneously, S3.31 was identified as a 
possible key interacting residue for CP55940, and this was subsequently proven via a S112G 
mutagenesis study.  
 Song et al docked the aminoakylindole ligand WIN55212-2 into a model of CB2
 
in order to 
investigate its selectivity for CB2
 
over CB1 (165). It was found that besides aromatic stacking with 
F3.25, F3.36, and W5.43 there is an additional fourth aromatic interaction with F5.46 in CB2, with 
the corresponding residue in CB1 being a valine. Subsequent mutation of F5.46 to valine decreased 
WIN55212-2 binding by 14 fold with no effect on other ligand classes, while mutation of the 
corresponding valine in CB1 to phenylalanine increased WIN55212-2 binding by 12-fold, 
highlighting the importance of this residue in the CB2 selectivity of WIN55212-2. 
 McAllister et al applied Monte Carlo/Stochastic Dynamics to models of CB1 with Y5.39F 
and Y5.38I mutations to investigate the importance of aromaticity and hydrogen-bonding capability 
on these residues (166). The modelling studies showed that loss of aromaticity resulted in a 
rearrangement of key residues within the receptor. They then tested this hypothesis in the lab by 
studying Y5.39I mutants of CB1, which showed loss of ligand binding and signal transduction, 
supporting their modelling observations. The same group then created an active-state model of CB1 
using the Conformational Memories technique which was aided by experimental data (167). 
Docking of the several ligands into both the inactive and active state models revealed several 
residues of interest, such as F3.25, F3.36, Y4.64, W5.43 and W6.48 which were then mutated in 
ligand-binding studies. A detailed functional analysis was carried out in a follow-up study, where 
modelling results suggested that F3.36 and W6.48 formed a toggle switch that is broken during 
receptor activation, supporting the results of previous studies (168). 
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 Another study utilizing the Conformational Memories technique by Kapur et al following 
mutagenesis studies of S2.60A and S7.39A in CB1 predicted that S7.39 induces a helix bend in 
TM7 that provides space for the binding of CP55940 (169). Modelling studies with the mutant 
receptor predicted an alteration to this binding space that precluded CP55940 binding.  
 Gouldson et al mutated S4.53 and S4.57 in CB2 to alanine and found that this reduced its 
affinity for SR144528 (170). The docking of SR144528 into a model of CB2 led to the proposal of 
a binding pose of SR144528 that involved hydrogen bonds with both the serines studied. Similarly, 
Zhang et al mutated W5.43 in the CB2 receptor to tyrosine, phenylalanine, and alanine following 
modelling studies by Montero et al that highlighted W5.43 as a possible interaction site for 
SR144528 (171,172).  The W5.43Y mutant retained CP55940 binding but had reduced affinity for 
WIN55212-2 and SR144528; the W5.43F and W5.43A mutations significantly affected the binding 
affinities of all three ligands. The authors then predicted the binding mode of CP55940, 
WIN55212-2, and SR144528 leading to the conclusion that both aromaticity and hydrogen bonding 
plays a role in ligand binding at W5.43. More recently, Sitkoff et al mutated F200 and S383 in CB1 
and proposed a binding mode for a new inverse agonist chemotype, the tetrahydroquinolines, based 
on the mutagenesis results and structure-activity relationships observed (173). 
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1.4 Fenofibrate derivatives as cannabinoid receptor ligands 
1.4.1 )LEUDWHV7KHUDSHXWLFXVHDV33$5ĮDJRQLVWV 
The fibrates are a class of small molecules that structurally resemble short chain fatty acids. The 
first fibrate to be used medicinally for hypercholesterolemia was clofibrate 19, which was 
discovered in 1961 and followed by gemfibrozil 20 and fenofibrate 21 (see Figure 1-15) (174). 
Fenofibrate itself is a prodrug, and is converted via ester hydrolysis to its active form fenofibric 
acid 22. The prominence of fibrates in hyperlipidaemia therapy fell following less than stellar 
performances in major clinical trials, safety concerns, and the emergence of HMG-CoA reductase 
inhibitors (more popularly known as statins) as the preferred drug of choice in such conditions 
(174). The use of fibrates, particularly gemfibrozil and fenofibrate, are currently supported for 
specific variants of metabolic disorders such as hypertriglyceridemia, mixed dyslipidemia, and 
isolated low levels of HDL (174). 
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Figure 1-15 Structure of fibrates 
 The mechanism of action of fibrates is complex, but primarily involves the activation of a 
group of receptors known as the peroxisome proliferator-activated receptors (PPARs), particularly 
33$5Į(175). The PPARs are nuclear receptors that modulate various physiological processes such 
as lipid metabolism, blood pressure, glucose control and insulin resistance.  Activation RI33$5Į
by the fibrates results in the expression of genes involved in multiple metabolic pathways, resulting 
in decreased triglyceride and very low density  lipoprotein (VLDL) levels, as well as increased 
HDL levels (176).  The structure of the ligand ELQGLQJ GRPDLQ RI 33$5Į WKH UHFHSWRU DOVR
contains a DNA binding domain and a ligand-dependent activating domain) in complex with a 
ligand GW409544 23 and co-activator peptide was first solved via X-ray crystallography in 2001; 
its structure is shown below in Figure 1-16 (177).   
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Figure 1-16 &U\VWDOVWUXFWXUHRI33$5ĮZLWKERXQG*: 
 
 1.4.2 Fenofibrate amide derivatives as cannabinoid receptor ligands 
It has been recently shown that fenofibrate, but not its active metabolite fenofibric acid, 
possesses agonist activity at both of the cannabinoid receptors with a binding affinity (pKi) of 6.32 
at CB1 and 6.97 at CB2
 
(Ki 480nM and 108nM respectively) (178,179). While it followed that a 
dual ligand, possessing agonist activity at the 33$5ĮUHFHSWRUDQGDQWDJRnist activity at the CB1 
receptor would have potential benefit in the treatment of obesity and associated hyperlipidemias, 
novel amide fenofibrate derivatives investigated were found to possess significant affinity for both 
cannabinoid receptors but lost 33$5Į activity (179). These derivatives along with their 
pharmacological properties at the cannabinoid receptors are shown in Table 1-2 and Table 1-3.  
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No R1 R2 pKi at CB1a 
% CB1
 
activation 
at 10 µM b pKi at CB2
a %  CB2 activation 
at 10 µM b 
24a 4-Cl (CH2)2OH - 112 ± 7 < 5   93 ± 9 
24b 4-Cl (CH2)4OH - 110 ± 29 6.42 144 ± 14 
24c 4-Cl (CH2)6OH - 125 ± 8 6.20 113 ± 6 
24d 4-Cl i-Pr - 105 ± 19 6.36 121 ± 3 
24e 4-Cl (CH2)5CH3 -   87 ± 13 5.92   84 ± 2 
24f 4-Cl CH2Ph - 113 ± 11 6.66 ± 0.02   84 ± 23 
24g 4-Cl piperidin-1-yl 6.99 ± 0.11 137 ± 6 7.82 ± 0.10 152 ± 10 
24h 4-Cl morpholin-4-yl 6.82 ± 0.16 149 ± 7 7.80 ± 0.06 153 ± 2 
24i 4-Cl 2-(pyrrolidin-1-yl)eth-1-yl - 101 ± 20 -   89 ± 15 
24j 4-Cl 2-(morpholin-4-yl)eth-1-yl - 123 ± 15 -   87 ± 8 
24k 4-Cl t-Bu - 108 ± 9 -   69 ± 10 
24l 4-Cl 4-methyl-piperazin-1yl -   94 ± 10 -   78 ± 10 
24m 4-Cl 4-(2-hydroxyethyl)-phen-1-yl - 101 ± 8 -   73 ± 10 
24n 4-Cl Ph -   87 ± 8 6.84 ± 0.16 104 ± 3 
Table 1-2 Pharmacological properties of an initial set of novel amide derivatives of fenofibrate at the cannabinoid receptors (179). 
Data represents mean values ± SEM of three independent experiments. If no SEM is shown a single experiment was performed.              
a Displacement of [3H]CP55940 in membrane homogenates of CHO cells transfected with human CB1 or CB2 receptors over 10 
concentration values; binding affinities (pKi) were determined using experimental IC50 values and the Cheng-Prusoff equation (21).    
b
 0HDVXUHPHQWRIHQKDQFHPHQWRI>6@*73Ȗ6 binding in membrane homogenates of CHO cells transfected with human CB1 or CB2 
receptors, expressed as % of basal binding at a single concentration of 10µM. 
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No R1 R2 pKi at CB1 a 
% CB1 activation 
at 10 µM b pKi at CB2
 a
 
% CB2 activation 
at 10 µM b 
25a 4-Cl CH2(2-F-Ph) -   83 ± 21 6.23 ± 0.11 75 ± 6 
25b 4-Cl CH2(3-F-Ph) -   87 ± 11 6.37 ± 0.08 69 ± 10 
25c 4-Cl CH2(4-F-Ph) - 100 ± 17 6.62 ± 0.06 80 ± 2 
25d 4-Cl CH2(2-Me-Ph) -   61 ± 18 5.94 ± 0.04 68 ± 9 
25e 4-Cl CH2(3-Me-Ph) -   85 ± 14 5.63 ± 0.11 39 ± 5 
25f 4-Cl CH2(4-Me-Ph) -   76 ± 15 5.88 ± 0.14 40 ± 2 
26a 4-Cl 2-F-Ph -   69 ± 16 5.94 ± 0.18 90 ± 4 
26b 4-Cl 3-F-Ph - 111 ± 11 5.48 ± 0.01 97 ± 10 
26c 4-Cl 4-F-Ph -   91 ± 2 5.87 ± 0.13 89 ± 6 
26d 4-Cl 2-Me-Ph - 100 ± 8 5.81 ± 0.03 89 ± 5 
26e 4-Cl 3-Me-Ph - 114 ± 8 6.12 ± 0.14 87 ± 4 
Table 1-3 Pharmacological properties of a second set of novel amide derivatives of fenofibrate at the cannabinoid receptors (179). 
Data represents mean values ± SEM of three independent experiments. If no SEM is shown a single experiment was performed.              
a Displacement of [3H]CP55940 in membrane homogenates of CHO cells transfected with human CB1 or CB2 receptors over 10 
concentration values; binding affinities (pKi) were determined using experimental IC50 values and the Cheng-Prusoff equation.             
b
 0HDVXUHPHQWRIHQKDQFHPHQWRI>6@*73Ȗ6 binding in membrane homogenates of CHO cells transfected with human CB1 or CB2 
receptors, expressed as % of basal binding at a single concentration of 10µM. 
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No R1 R2 pKi at CB1 
% CB1 activation 
at 10 µM pKi at CB2 
% CB2 activation 
at 10 µM 
27a 2-Me
 
morpholin-4-yl -   99 ± 10 7.25 ± 0.12 148 ± 24 
27b 3-Me morpholin-4-yl -   99 ± 7 - 104 ± 5 
27c 4-Me morpholin-4-yl - 103 ± 18 6.51 ± 0.02 160 ± 9 
27d 3-CN morpholin-4-yl - 107 ± 11 - 98 ± 1 
27e 3-Cl morpholin-4-yl - 101 ± 6 - 82 ± 4 
27f 2-F morpholin-4-yl 7.04 ± 0.07 130 ± 19 6.84 ± 0.07 119 ± 19 
27g 3-F morpholin-4-yl -   89 ± 9 - 116 ± 5 
27h 4-F morpholin-4-yl -   89 ± 7 6.64 ± 0.15 135 ± 7 
27i 3-NO2 morpholin-4-yl -   92 ± 14 - 106 ± 14 
27j H morpholin-4-yl -   92 ± 18 6.52 ± 0.01 137 ± 8 
28a 2-Me piperidin-1-yl - 105 ± 9 - 102 ± 23 
28b 3-Me piperidin-1-yl - 102 ± 14 - 77 ± 14 
28c 4-Me piperidin-1-yl 7.59 ± 0.15 174 ± 20 7.54 ± 0.14 155 ± 4 
28d 3-CN piperidin-1-yl - 112 ± 12 - 108 ± 1 
28e 4-CN piperidin-1-yl - 104 ± 4 - 114 ± 19 
28f 3-Cl piperidin-1-yl -   97 ± 8 - 82 ± 18 
28g 2-F piperidin-1-yl - 119 ± 13 - 134 ± 4 
28h 3-F piperidin-1-yl -   87 ± 15 - 110 ± 9 
28i 4-F piperidin-1-yl 7.34 ± 0.15 140 ± 22 7.85 ± 0.08 129 ± 9 
28j H piperidin-1-yl - 127 ± 6 - 124 ± 3 
Table 1-3 (cont.) Pharmacological properties of a second set of novel amide derivatives of fenofibrate at the cannabinoid receptors. 
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The initial set of compounds 24a-n, intended as a broad structural exploration, revealed 
some preliminary structure-activity relationships. Compounds with cyclic carboxamide N-
substituents (24f-h,n) showed higher binding affinities to CB2 than their alkyl and hydroxyalkyl 
counterparts (24a-e), alluding to possible steric constraints within the binding site. Similar 
conclusions could not be made for CB1 due to the limited data available. These compounds also 
displayed varied efficacy, evidenced by the fact that the four compounds with the highest binding 
affinities (24f-h,n) consisted of two agonists, one inverse agonist and one neutral antagonist for 
both receptors. These four compounds were subsequently developed further to explore substitution 
effects at the R1 and R2 regions of the fenofibrate scaffold. 
Introduction of a fluoro or methyl substituent to the benzyl functionality 25a-f did not 
improve CB2 affinity, although the methyl analogues showed lower binding, once again suggesting 
some possible steric constraints. However, this effect was not replicated in the phenyl analogues 
26a-e, as substitution of the phenyl decreased CB2 affinity in an analogous manner regardless. 
Substitution of the benzophenone moiety in the morpholinyl and piperidinyl analogues 27a-28j 
similarly did not improve CB2 affinity significantly compared to 24g and 24h, although most of the 
compounds assayed showed comparable nanomolar affinity. Taking into account the varied 
affinities of 24a-n, the relevance of the carboxamide substituent towards CB2 receptor affinity is 
clearly evident. Functionally, 25a-26e all displayed inverse agonism at CB2 and either inverse 
agonism or neutral antagonism at CB1, indicating that the efficacy of these analogues may be 
dependent more on the predominantly aromatic nature of the carboxamide substituent rather than 
any specific substitution effects. Modification of the benzophenone moiety appears to be slightly 
more significant in this respect, as demonstrated by the fact that the morpholinyl and piperidinyl 
analogues displayed more varied efficacy at the CB2
 
receptor. All compounds substituted at 
position 2 and 4 of the R1 aryl exhibited some degree of agonist activity, while the 3-substituted 
compounds, with the exception of the 3-fluoro compounds 27g and 28h, exhibited neutral 
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antagonist or inverse agonist character. In contrast, substitution effects had less of an influence on 
CB1 activity, with all morpholinyl and piperidinyl derivatives displaying neutral antagonist/inverse 
agonist activity, with the exception of the fluoro substituted 27f, 28g, 28i, the 4-methyl substituted 
28c, and the unsubstituted 28j, which showed some degree of agonist activity. 
While the findings of this study serves as a useful starting point in the development of the 
fenofibrate scaffold as a new class of cannabinoid receptor ligands, the structure-activity 
relationships derived were not particularly distinct. A molecular modelling study incorporating the 
pharmacological data obtained would allow for the rationalization of these findings and a more 
focused approach in developing further fenofibrate amide derivatives as cannabinoid receptor 
ligands. This effort to employ a structure-based approach within this research area represents the 
main focus of this doctoral dissertation. 
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2 AIMS AND OBJECTIVES 
This project aims to construct validated homology models of the human cannabinoid receptors CB1 
and CB2, which will be refined using molecular dynamics simulations in a fully-hydrated lipid 
bilayer, for use in rational drug design. Specifically, these models are constructed with a view to 
study the binding of novel cannabinoid receptor ligands that are based on the PPARĮ agonist 
fenofibrate. The information obtained from analysing their binding will be used to rationalize 
previous pharmacological data and to design further novel derivatives using a structure-based 
approach. These novel derivatives will subsequently be synthesized and their pharmacological 
properties determined in order to evaluate our modelling predictions for improved future drug 
design. 
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3 MOLECULAR MODELLING OF THE CANNABINOID 
RECEPTORS AND STRUCTURE VALIDATION 
3.1 Construction and assessment of homology models 
3.1.1 Template selection and sequence alignment 
The amino acid sequences of both cannabinoid receptors and all GPCRs whose crystal structure had 
been solved to date were obtained from the UniProt Knowledgebase (UniProt Accession Numbers: 
P21554 (human CB1), P34972 (human CB2), P02699 (bovine rhodopsin), P31356 (squid 
rhodopsin), P07700 (avian adrenoceptor ȕ2), P07550 (human adrenoceptor ȕ2), P29274 (human 
adenosine A2A), P35462 (human dopamine D3), P61073 (human chemokine CXCR4), and P35367 
(human histamine H1)) (180). In order to determine which GPCR would be the most suitable 
template, the amino acid sequence of each GPCR was individually aligned against the cannabinoid 
receptors using the EMBOSS Water tool (a modified Smith-Waterman algorithm)  available 
through the European Bioinformatics Institute server (181). The results of these pairwise 
alignments are presented in Table 3-1. 
GPCR with known structure % Identity with CB1 % Identity with CB2 
Bovine rhodopsin 25.4  21.1 
Squid rhodopsin 23.5  23.2 
$YLDQDGUHQRFHSWRUȕ1 25.9 26.5 
Human DGUHQRFHSWRUȕ2 25.7 25.0 
Human adenosine A2A 28.0 27.1 
Human dopamine D3 21.6 20.5 
Human chemokine CXCR4 20.8 23.4 
Human histamine H1 18.9 17.6 
Table 3-1 Pairwise sequence alignment of the CB1 and CB2 cannabinoid receptors against GPCRs 
with known crystal structures. The highest sequence identities are highlighted in bold. 
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Overall, sequence identity between the cannabinoid receptors and the other GPCRs was 
found to be poor with all pairwise sequence identities below 30%, a critical level in protein-
sequence analysis where conventional sequence alignment methods are more likely to produce 
errors (135). However, in the case of GPCRs this low sequence identity is compensated by their 
well-defined seven transmembrane structure; sequence similarity in the transmembrane regions are 
generally high, with insertions and deletions being much more likely to occur in the loop regions. 
The adenosine A2A receptor showed the highest sequence identity with both cannabinoid receptors 
(28.0% identity with CB1 and 27.1% identity with CB2 respectively). This is in agreement with the 
phylogenetic analysis results presented by Fredriksson et al, where the cannabinoid and adenosine 
receptors are classified in the same subgroup (1). As such, the adenosine A2A receptor was selected 
as the template for our homology modelling and for further refinement of the sequence alignment. 
A multiple sequence alignment of  the human CB1, CB2 and A2A receptors was then done 
using CLUSTALW2 (182), with the Gonnet protein weight matrix and a gap open penalty set to 25. 
The resulting alignment was then manually edited using JALVIEW (183), in order to remove gaps 
and maximize sequence similarity in the TM regions. This final sequence alignment, with the N and 
C termini (residues 1-112 and 418-473 of CB1, residues 1-29 and 320-360 of CB2) omitted, is 
presented in Figure 3-1. 
The sequence alignment produced showed the most conserved residues in each helix, as 
defined by Ballesteros-Weinstein (N1.50, D2.50, R3.50, W4.50, P5.50, P6.50, P7.50), to be present 
and aligned (47). The exception to this was P5.50, which is not conserved in either cannabinoid 
receptor. The second most conserved residue within TM5 is Y5.58, and consequently using the 
µVWUXFWXUDODOLJQPHQW¶GHWDLOHGLQ%UDPEOHWW et al (150), Y5.58 in the A2A receptor was aligned with 
Y294 in CB1 and Y209 in CB2. Other highly conserved motifs, such as the DRY motif in TM3, the 
CWXP motif in TM6, and the NPXXY motif in TM7 were also found to be present and aligned. 
Cysteine residues involved in disulfide bridge formation in the A2A receptor were not found to be 
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conserved. Previous mutagenesis experiments, however, have shown that a disulfide bridge is likely 
to exist between C257-C264 for CB1 and C174-179 for CB2 respectively (170,184). 
 
 
Figure 3-1 Sequence alignment of human cannabinoid CB1, cannabinoid CB2 and adenosine A2A 
receptor, with N and C termini excluded for clarity. * indicates residue identity, : high residue 
similarity, and . low residue similarity. The TM regions, as defined in reference (28), are 
highlighted yellow. The most conserved residues of each TM helix are highlighted turquoise. The 
2nd most conserved residue of TM5, Y5.58, is highlighted red. Disulfide bridges were constructed 
between the cysteine residues highlighted in green. 
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3.1.2 Initial model construction and assessment  
The coordinates of the crystal structure of the adenosine A2A receptor bound to an inverse agonist 
was obtained from the PDB (PDB code: 3EML) (28). Using these coordinates as a template and the 
sequence alignment described in section 3.1.1, MODELLER (185), was used to generate an initial 
model of the human CB1 and CB2 receptors. The N-termini (residues 1-112 of CB1 and 1-29 of 
CB2) and C-termini (residues 418-473 of CB1 and 320-360 of CB2) of both receptors were 
truncated. A disulfide bridge was constructed between C257-C264 and C174-179 for CB1 and CB2 
respectively. 50 models were generated for both CB1 and CB2. Models were evaluated using high-
resolution DOPE scores, which are based on a statistical potential, generated by MODELLER, and 
the models with the best DOPE score was selected for further refinement. 
 As the template structure 3EML did not possess a 3rd intracellular loop due to its 
replacement with T4L, this loop (30 and 17 residues long in CB1 and CB2 respectively) was 
subject to further refinement using the loop modelling class within MODELLER. 25 loop 
conformations were generated for each model. These conformations were then visually inspected to 
ensure a reasonable loop conformation (defined as the absence of breaks or knots within the loop, 
and the loop not intruding into the transmembrane region). The models possessing reasonable loop 
conformations with the best DOPE scores were then selected as our initial structures for the next 
stage of molecular dynamics. 
 The selected structures were then subject to energy minimization to relieve any steric 
clashes that could have arisen during model construction. The stereochemical quality of each 
structure was then assessed by generating Ramachandran plots using PROCHECK (128). The 
energy-minimized structures and their respective Ramachandran plots are shown in Figure 3-2. 
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Figure 3-2 Homology models of the cannabinoid receptors and their corresponding Ramachandran 
plots. The contours on each plot were derived from the phi and psi angles of 118 protein crystal 
structures. The red, yellow, beige, and white regions represent the most favoured, additionally 
allowed, generously allowed and disallowed regions respectively. Glycine and proline residues are 
represented as triangles, whereas all other residues are represented as squares.  
 
 
 In both cases, energy minimization converged to acceptable potential energy values before 
all iterations were completed. The Ramachandran plot of CB1 showed 84.4% of residues to be in 
the most favoured regions, with 13.1% in the additional allowed regions, 1.4% in the generously 
allowed regions, and 1.1% in disallowed regions. The Ramachandran plot of CB2 showed 89.3% of 
residues to be in the most favoured regions, with 10.0% in additionally allowed regions, 0.7% in the 
generously allowed regions, and 0.0% in the disallowed regions. 
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Our results show 98.9% of residues in CB1 and 100% of the residues in CB2 to be in 
conformations observed in typical crystal structures, although ideally at least 90% of these residues 
should be in the most favoured regions (186). Further visual analysis of residues in the disallowed 
regions revealed that these residues were all located in the 3rd intracellular loop of which our 
adenosine A2A crystal structure did not provide a template, and is not known to participate in 
ligand binding. As such, these structures were deemed to be of sufficient quality to be further 
refined via molecular dynamics simulations.  
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3.2 Molecular dynamics simulations of the cannabinoid receptors 
3.2.1 Selection of force field parameters 
Taking into consideration the computational resources available and the length of simulations to be 
run, the GROMOS 53a6 united-atom force field (140) was selected as the primary force field for all 
molecular dynamics simulations. The united-atom approach (non-polar hydrogens are not explicitly 
represented) substantially reduces computational cost, and is particularly advantageous in the 
simulation of lipid bilayers. The GROMOS 53a6 force field has been parameterized to reproduce 
the free enthalpies of solvation of amino acid analogues in cyclohexane and water, and the 
thermodynamic properties in the liquid phase of a range of small polar molecules (140). This force 
field has also been subsequently validated for simulations of protein, peptides and DNA in water 
(187).  However, it has been shown that this force field parameter set does not adequately 
reproduce the correct area per lipid, which is the primary property used in the validation of 
computational models of lipid bilayers (188). Over the years additional parameters for the treatment 
of lipids using the GROMOS force fields have been proposed, such as those presented by Berger et 
al (a combination of parameters from the GROMOS and OPLS force field), Kukol et al, and Poger 
et al (188±190). The parameters presented by Poger et al have been shown to not only reproduce 
the correct area per lipid for various lipid simulations, but have also validated against other 
experimental data, such as volume per lipid, bilayer thickness, isothermal area compression 
modulus, deuterium order parameters, acyl chain conformations, and headgroup orientation and 
hydration (191). These parameters were therefore selected to supplement the parameters within the 
GROMOS 53a6 force field (see section 8.1 for details on all parameters used in molecular 
dynamics simulations). 
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3.2.2 Lipid bilayer construction and equilibration 
The coordinate file of a hydrated, equilibrated 128 lipid POPC (Figure 3-3) bilayer along with 
additional lipid parameters for the GROMOS 53a6 force field were obtained from Poger et al (188).  
 
 
Figure 3-3 Structure of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) 29 
 
This coordinate file was then resized using the tools available within GROMACS to produce a fully 
hydrated, 316 lipid bilayer of dimensions 124 x 124 x 114 Å. This system then was subject to 
energy minimization. The minimized structure was then subjected to 100ps of molecular dynamics 
using the NVT (constant number of atoms, volume, and temperature) ensemble, followed by 25ns 
using the NPT (constant number of atoms, pressure and temperature) ensemble. The results of this 
simulation are presented in Figure 3-4. 
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Figure 3-4 Fluctuations in: (A) Temperature (B) Pressure (C) Potential Energy (D) Box lateral 
dimensions of a POPC bilayer during 25ns of NPT molecular dynamics simulation. 
  
Energy minimization converged to acceptable potential energy levels before all iterations of 
energy minimization were completed.  The temperature, pressure, and potential energy of the lipid 
bilayer showed almost immediate equilibration and remained stable throughout the simulation. 
Lateral dimensions of the bilayer decreased for the first 10ns of dynamics and remained stable 
thereafter. Final dimensions of the lipid bilayer were 98.9 x 98.9 x 128 Å. This translated to an area 
per lipid (calculated as the lateral area of the box divided by the number of lipids in a single leaflet 
of the bilayer) of approximately 62.0 Å2. This value is comparable to that obtained by Poger et al of 
63.8 Å2, and is also well within the experimental data range of 54.0 ± 68.3 Å2 (191±195). Visual 
inspection of final coordinates showed the lipid bilayer to be well-structured, with the absence of 
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any water molecules within the membrane, as shown in Figure 3-5. As our results indicated that the 
lipid bilayer constructed was equilibrated, these final coordinates were used for the subsequent 
embedding of our homology models.  
 
 
Figure 3-5 The hydrated POPC lipid bilayer system 
 
3.4.1 Embedding of homology models into the lipid bilayer 
Models of each cannabinoid receptor were manually placed in the POPC bilayer using the Visual 
Molecular Dynamics (VMD) program (196). Placement was guided by the alpha-helicity of the 
transmembrane regions and arginine/lysine patches at the membrane interface that are hypothesized 
to anchor the helices via interaction with the phospholipid head groups (150). The receptor was 
then embedded within the POPC bilayer using the g_membed tool within GROMACS (197). 
Embedding was conducted over 1000 MD steps, using a scaling factor of 0.5. Counter-ions where 
then added to the system before it was subject to energy minimization. 
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Embedding of the CB1 and CB2 receptors resulted in the removal of 36 and 30 lipid 
molecules respectively. Energy minimization converged to acceptable potential energy levels 
before all iterations were completed. The resulting structures are shown in Figure 3-6. 
 
 
Figure 3-6 The cannabinoid receptors embedded within a POPC bilayer. 
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3.2.4 System equilibration 
In order to equilibrate both proteins within the POPC bilayer, each system was subject to 100ps of 
molecular dynamics using the NVT ensemble, followed by 70ns using the NPT ensemble. Position 
restraints with a force constant of 1000 kJ/mol/nm2 were initially applied on the protein and 
released in stages over the first 20ns of simulation (see Figure 3-7). The results of these simulations 
are presented in Figure 3-8. 
 
Figure 3-7 Schematic representation of molecular dynamics for system equilibration 
 
Figure 3-8 Equilibration of the cannabinoid receptors in a POPC bilayer 
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 Temperature and pressure of both simulations showed almost immediate stabilization and 
remained as such throughout the simulation, whereas potential energy decreased with release of the 
position restraints and remained stable after 20ns (see Appendix 1). Box lateral dimensions 
stabilized after 30ns for CB1 and 50ns for CB2, with slight fluctuations within approximately 2Å. 
The root mean square deviation (RMSD) of the protein backbone for both receptors increased 
significantly at 20ns following release of position restraints and stabilized after 50ns of simulation, 
with an RMSD deviation from the initial structure of approximately 5Å for CB1 and 3Å for CB2. 
Such values indicate significant deviation from the initial structure but are typical of molecular 
dynamics simulations of homology models, as the overall structure of the initial model would be 
more similar to the structure of the template used. Movement of the loop regions, rather than the 
transmembrane helices, likely contributed significantly more to the RMSD deviations observed. 
 The lateral dimensions of a lipid bilayer system present an indirect measurement of the area 
per lipid. While our results thus indicate the area per lipid to be stable, the presence of the receptor 
disallows calculation of area per lipid directly from the lateral dimensions of the system. Area per 
lipid was thus derived using GridMAT-MD (198), with the final area per lipid, taking into account 
protein atoms, calculated to be 58.6Å for the CB1 system and 59.0Å for the CB2 system. While 
these values are much lower than those obtained for the pure lipid system, it should be noted that 
the effect of a membrane protein on area per lipid is currently still unknown, and they remain 
within the range of experimental data of 54.0 ± 68.3 Å2 (192±195). Protein backbone RMSD, which 
is a commonly used parameter to infer protein stabilization in molecular dynamics, showed both 
receptors to be stable after 50ns of simulation. Interestingly, the average RMSD deviation for CB1 
was significantly higher compared to CB2, indicating a starting structure that was further from its 
stable state. These results thus indicated both protein and lipid bilayer to be equilibrated. 
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3.2.5 Production simulations 
In order to generate the conformational ensemble required to produce a validated model, the 
equilibrated systems were each given fresh velocities and subjected to further molecular dynamics 
until a stable protein backbone RMSD was achieved. The lowest energy conformations following 
protein stabilization where then extracted from this ensemble to undergo structure validation. The 
results are presented in Figure 3-9. 
 
 
Figure 3-9 Production run of the cannabinoid receptors 
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 For CB1, total production simulation time was 150ns. RMSD of protein backbone showed 
protein stabilization after approximately 80ns of simulation. For CB2, total production simulation 
time was shorter at 100ns as the receptor appeared to stabilize after approximately 40ns of 
simulation. The stabilization of protein backbone RMSD following only minor deviation from the 
initial structure possibly indicate that the dynamics were sampling local minima in their respective 
energy landscapes. The lowest energy conformations for CB1 were extracted from the time steps of 
80.6ns, 109.8ns, 135.9ns, 145.5ns, while the lowest energy conformations for CB2 were extracted 
from the time steps of 81.2ns, 98.6ns, 58.2ns, and 96.0ns. 
 
3.2.6 Molecular dynamics of the CB1 cannabinoid receptor with bound antagonist 
Preliminary analysis of the CB1 receptor however, revealed that the binding site closes during 
molecular dynamics, thus precluding ligand docking and model validation. The molecular surface 
of the CB1 receptor binding site is shown in comparison to the CB2 receptor in Figure 3-10. 
Several strategies were subsequently employed to facilitate docking to our CB1 models, such as 
docking with flexible protein side chains, scaling of van der Waals radii, and active site 
pressurization (199). None of these methods proved to be particularly successful at keeping the 
binding site open and facilitating the docking of ligands. As such, both the equilibration and 
production simulations for the CB1 receptor were rerun, but with the CB1-selective antagonist 
SR141716 (rimonabant) bound to the keep the active site open. 
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Figure 3-10 Molecular surface of the CB1 and CB2 receptor binding site. The closed nature of 
the CB1 receptor binding site precluded ligand docking. 
 
 Initial placement of the ligand was done using docking analysis and guided by mutagenesis 
data (167,184). The ligand was docked into the pre-equilibration model of the CB1 receptor using 
AutoDock4 (see section 8.1 for docking procedure and parameters used), and the lowest energy 
conformation that showed the best agreement with mutagenesis data was selected. The chosen 
conformation is shown in Figure 3-11, where SR141716 shows interaction with F3.36 and W6.48, 
with C7.42 in close proximity. Residue W5.43 did not appear to be within interacting distance in 
this model. 
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Figure 3-11 Initial placement of SR141716 binding to the CB1 binding pocket. The 
ligand is shown in red while residues known to affect SR141716 through mutagenesis 
studies are shown in green. 
 
 
 Partial charges used in ligand topology were assigned by combining the partial charges of 
individual functional groups available within the GROMOS 53a6 force field. For functional groups 
that were not parameterized in GROMOS 53a6, partial charges were obtained using the Automated 
Topology Force Field Builder (ATB) repository, which combines quantum-mechanical calculations 
with a knowledge-based approach to ensure compatibility with a specific GROMOS force field 
parameter set as far as possible (see Appendix II for full description of partial charges) (200). 
 Simulation of the receptor with bound SR141716 successfully kept the binding pocket open 
throughout all molecular dynamics runs. During equilibration, temperature and pressure stabilized 
almost immediately, while the lateral dimensions of the lipid bilayer and protein backbone RMSD 
stabilized after approximately 50ns of simulation (see Appendix I).  
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 The results for the production run of the CB1 receptor with SR141716 bound are shown in 
Figure 3-12. Total simulation time was 350ns, and RMSD of the protein backbone in the 
transmembrane regions showed protein stabilization after approximately 220ns of simulation. The 
lowest energy conformations were extracted from the time steps of 240.7ns, 246.2ns, 262.9ns, 
271.5ns, and 344.2ns. Analysis of the protein secondary structure showed slight unwinding of the 
alpha helices which was not seen in the CB2 simulations and have been previously associated with 
the GROMOS 53a6 force field (201). 
 
 
 
Figure 3-12 Production run of cannabinoid CB1
 
receptor with bound SR141716 
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3.3 Model validation 
All structures extracted from the conformational ensemble generated via molecular dynamics 
simulations, in addition to the pre-equilibration structures, were then subjected to docking analysis 
in order to assess the ability of each model to reproduce experimental data. Ideally, for the purpose 
of binding mode prediction, one would validate a homology model via the reproduction of the 
experimentally determined binding mode of another ligand. In the absence of any crystal structure 
of either receptor this was not possible, and as such we have validated our models using docking 
evaluations and enrichment studies that demonstrated the ability of our model to predict the binding 
affinities of known ligands and distinguish between known ligands and decoys. Each model was 
assessed for its ability to correctly rank ligands according to their relative potency, as measured via 
WKH6SHDUPDQ¶VUDQNFRUUHODWLRQFRHIILFLHQW ȡ, and their ability to predict ligand binding affinities, 
as measured via the coefficient of determination (R2). The models were then assessed in their ability 
to distinguish between known binders and a set of drug-like decoys in a virtual screening exercise, 
which was evaluated by plotting their corresponding Receiver Operating Characteristic (ROC) 
curves and area under the curve (AUC). Additionally, the predicted binding poses of several well 
characterized ligands were analysed in order to assess their agreement with mutagenesis data. 
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3.3.1 Binding affinity prediction of known ligands 
A series of ligands, comprising of both agonists and antagonists capable of binding to each 
cannabinoid receptor, with experimental Ki values ranging over approximately 5 logarithmic values, 
were collected from literature (see Appendix III for full list of ligands and experimental pKi values) 
(64,69,80,202±239). These ligands were individually docked to each receptor model extracted from 
the molecular dynamics simulations (see section 8.1 for full docking procedure and parameters 
used). The results from the best-performing model of the CB1 receptor (time step of 240.7ns) and 
CB2 receptor (time step of 96.0ns) are shown in Figure 3-13. 
 
Figure 3-13 Correlation between predicted pKi values and experimental data. Models were 
extracted from time step of 240.7ns and 96.0ns for the CB1 and CB2 receptor respectively. R2 
YDOXHVDQGȡYDOXHVDUHGLVSOD\HGIRUHDFKOLJDQGVHW)RUERWKFRHIILFLHQWVDYDOXHRILQGLFDWHV
perfect positive correlation, while a value of 0.0 indicates random distribution. 
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 For CB1, after removal of outliers, the R2 YDOXH ZDV  DQG WKH ȡ YDOXH  IRU
agonists, while for antagonists the R2 YDOXH ZDV  DQG WKH ȡ YDOXH  For CB2, after 
removal of outliers, the R2 value was 0.565 DQGWKHȡYDOXH 0.857 for agonists, while for antagonists 
the R2 value was 0.712 DQGWKHȡ value 0.853. These values indicated significant predictive power 
in the ranking of ligands based on potency and in predicting binding affinities, particularly for 
antagonist ligands. An analysis of the outliers removed showed that they consisted mostly of 
compounds with non-typical cannabinoid ligand scaffolds, or were compounds with significantly 
higher experimental binding affinities compared to other structurally similar compounds, thus likely 
indicating the scoring function applied was unable to account for the specific interactions that 
governed their high experimental binding affinity.    
The higher correlation between predicted and experimental binding affinities of antagonist 
ligands (0.710 for antagonists versus 0.364 for agonists in CB1; 0.712 for antagonists versus 0.565 
for agonists in CB2) was not entirely unexpected, as both models were constructed based on the 
inactive-state structure of the adenosine A2A receptor bound to an inverse agonist, and would 
arguably therefore be more likely to remain in a conformation favouring antagonist binding 
considering the nanosecond time scale of the simulations. Moreover, CB1 was simulated with the 
antagonist SR141716 bound, likely further biasing the conformations sampled towards the inactive 
state. These values were comparable with those from previous studies that assessed scoring 
functions using a wide range of protein-ligand crystal complexes, showing that even using 
experimental structures gave correlations of 0.5-0.7 at best (145±147). One interesting observation 
was that the ranges of predicted pKi values were much smaller than their corresponding 
experimental range. This is also consistent with previous findings highlighting the fact that many 
scoring functions are unable to adequately predict the binding affinities of complexes with very 
high or very low affinities, and frequently underscore or overscore these complexes (147). 
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 It should be noted that the ability of any particular docking evaluation to successfully 
predict binding affinities is a complex function governed by several factors besides the accuracy of 
the protein structure, such as the docking algorithm employed, scoring function used, and the ligand 
sets tested (144,145,240). While it would therefore be imprudent to conclude on the accuracy of our 
CB1 and CB2 models based on these results alone, they do provide some degree of confidence on 
the ability of our models to be used as a predictive tool in rational drug design. 
3.3.2 Enrichment studies 
All ligands described in section 3.3.1 were used as the active set (i.e. known binders), regardless of 
whether they were agonists or antagonists. For the decoys, a set of 1000 drug-like decoys which 
have been used in previous enrichment studies was downloaded from Schrödinger (132). In order to 
make the decoy set more comparable to the active set, due to the inherent limitation of current 
scoring functions which are biased towards compounds with high molecular weight 
(144,147,240,241), we applied a molecular weight cut-off of 500 Daltons to the decoy set, which 
resulted in a final decoy set of 837 molecules. 
 Both sets of ligands were then docked into both receptor models using the same procedure 
and docking parameters as previously described. The docked molecules were then ranked according 
to the lowest predicted binding energy obtained. ROC curves were then plotted and their 
corresponding AUCs calculated using GraphPad Prism. The results are presented in Figure 3-14.  
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Figure 3-14 ROC curves for CB1 and CB2 receptor models. The line of identity (black) represents 
the expected line in completely random selection, which would result in an AUC of 0.5.   
The AUC obtained for the ROC curves for CB1 and CB2 were 0.75 and 0.70 respectively, 
which indicate a significant ability to distinguish between the active compounds and the decoys. 
The higher AUC for CB1 compared to CB2, particularly when focusing on the top ranking 
compounds, was slightly unexpected considering the CB2 model performed better in binding 
affinity prediction and ranking power. An analysis of the top ranking decoys which contributed 
significantly to the false positive rate at the initial part of the test revealed them to be mostly 
compounds of high molecular weight (in excess of 450 Daltons), once again highlighting the 
limitations of current scoring functions and the need to account for such biases in 
enrichment/virtual screening protocols. The fact that our CB2 model was in the apo form, with an 
open binding pocket, as compared to our CB1 model which was simulated with a bound ligand 
(subsequently removed), resulting in a tighter binding pocket, could have contributed to these 
findings as these compounds likely experienced more penalties due to steric clashes when scored in 
the CB1 model. Based on the ROC curves obtained and taking into consideration the diversity the 
active set used which also included compounds with moderate binding affinities (pKi values 
between 5 and 7), these enrichment studies provided additional support to the validity of our 
models in providing a reasonable representation of each receptor.   
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3.3.3 Binding mode assessment 
3.3.3.1 Predicted binding of SR141716, WIN55212-2, and CP55940 to the CB1 receptor 
The predicted binding poses of SR141716, WIN55212-2 and CP55940 in the CB1 receptor 
are shown in Figure 3-15, along with residues known to affect their binding through mutagenesis 
studies (see Appendix IV for full list of residues and references) (166,167,169,184,242±248). 
SR141716 showed interaction F3.36 and W6.48, with C7.42 in the close vicinity, but not W5.43. 
WIN55212-2 also showed interaction with F3.36 and W6.48, but not with D2.50, G3.31, W5.43, 
and Y5.39. CP55940 showed interaction with M6.55, but not with K3.28, L3.29, Y5.39, C6.47, and 
S7.39. 
 The predicted binding poses only showed interactions with some of the residues implicated 
via mutagenesis studies. In most cases, especially for agonists, many of these key residues did not 
appear to form part of the binding pocket or were not within interacting distance. For SR141716, 
which was re-docked and essentially reproduced the binding mode adopted throughout the 
simulations, only W5.43 did not interact with the ligand, and appeared to be directed towards the 
lipid bilayer. For WIN55212-2, the aromatic residues Y5.39 and W5.43 appeared to be directed 
towards the lipid bilayer, D2.50 was located deep within the binding pocket while G3.31 was also 
located on the side of TM3 facing the membrane. The interaction of SR141716 and WIN55212-2 
with both F3.36 and W6.48 was encouraging, as there is strong evidence suggesting these two 
residues form a toggle switch that plays a crucial role in CB1 receptor activation (168). For 
CP55940, the only non-interacting residue forming part of the binding pocket was L6.52, while 
K3.28, Y5.39, C6.47 and S7.39 had conformations that precluded interaction with the ligand. Once 
again considering the bias of our model towards antagonist binding, these findings were not entirely 
unexpected. The conformation of K3.28, which seemed to be interacting with the phospholipid 
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headgroups of the lipid bilayer, is agreement with the hypothesis that arginine/lysine patches help 
anchor the receptor to the membrane (150).  
 
Figure 3-15 The predicted binding poses of selective CB1
 
antagonist SR141716 (A), CB1 agonist 
WIN55212-2 (B), and non-selective agonist CP55940 (C) to the cannabinoid CB1 receptor. 
Residues known to affect ligand binding in mutagenesis studies are highlighted in green. Several 
residues in TM2 of the receptor have been removed to aid visualization. Only polar hydrogens are 
shown. 
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 Analysis of the predicted binding poses of other antagonist ligands of the diarylpyrazole 
class, such as SR144528, SR147778, and AM281, showed similar predicted binding poses to 
SR141716 (data not shown). 
3.3.3.2 Predicted binding of SR144528, WIN55212-2, and CP55940 to the CB2
 
receptor  
The predicted binding poses of SR144528, WIN55212-2 and CP55940 in the CB2 receptor 
are shown in Figure 3-16, along with residues known to affect their binding through mutagenesis 
studies (see Appendix IV for full list of residues and references) (164±166,170,171,249±255). The 
binding mode for SR144528 showed interaction with W5.43 but not S4.53, S4.57, and C175. 
WIN55212-2 showed interaction with W5.43, but not C174, C175, C179, F5.46, W4.50 and W4.64. 
CP55940 showed interaction with W5.43 and W6.48, but not C174, C179, K3.28, S3.31, W4.50 
and W4.64. 
 
 
 
 
 
 
 
 
 
84 
 
 
Figure 3-16 The predicted binding poses of selective CB2
 
antagonist SR144528 (A), selective CB2 
agonist WIN55212-2 (B), and non-selective agonist CP55940 (C) to the cannabinoid CB2 receptor. 
Residues known to affect ligand binding in mutagenesis studies are highlighted in green. Several 
residues in TM2 of the receptor have been removed to aid visualization. Only polar hydrogens are 
shown. 
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As in the CB1 receptor, the predicted binding poses showed interaction with only some of 
the residues implicated in their binding. However, the predicted interaction of all three ligands with 
W5.43, particularly hydrogen bonding between W5.43 and CP55940, was highly encouraging as 
this residue has been shown to be crucial in the binding of all three ligands (171). Several key 
residues were not located within the binding pocket and were not within interacting distance.  For 
SR144528, S4.53 and S4.57 appeared to be interacting with and stabilizing TM3, while the 
conformation of the 2nd extracellular loop did not allow interaction of C175 with the ligand in the 
binding pocket. Loop conformations, particularly of those longer than ten residues, are extremely 
hard to predict due to their flexibility, and are thus often missing from crystal structures. Similarly, 
for WIN55212, C174, C175, C179 and W4.64 are all located within the second extracellular loop 
and not within range for ligand interaction. F5.46 and W4.50 did not appear to be extending into the 
binding pocket, though F5.46 was found to be within interacting range with F3.36, which was in 
turn found to be interacting with the ligand. These residues, along with F3.25 and W5.43, have been 
previously proposed to form an aromatic stacking network with WIN55212-2 (165). For CP55940, 
the residues K3.28, S3.31, and W4.50 were all either not located in the binding pocket or had side 
chain orientations that did not allow for interaction with the ligand. Interestingly, both agonists 
WIN55212-2 and CP55940 were here found to be individually interacting with both residues of the 
F3.36/W6.48 toggle switch, which themselves were interacting as expected in our inactive state 
model. 
 Analysis of the predicted binding poses of other antagonist ligands of the same 
diarylpyrazole class as SR144528, such as SR141716, SR147778, and AM281, showed similar 
predicted binding poses (data not shown). Additionally, most of the ligands docked showed 
interactions with V6.51, L6.52, M6.55 and L6.59, which have been experimentally shown to be 
accessible within the ligand binding site crevice (252). 
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3.3.3.3 Binding mode assessment conclusions 
 While it is possible to attribute the ability of some of the key residues described to affect 
ligand binding in mutagenesis studies to subtle changes in the global conformation of the receptor 
rather than conclude that they are in an incorrect conformation in our model, in the absence of a 
crystal structure neither claim can be positively confirmed. Certainly, residues in the second 
extracellular loop such as C174 and C179 in the CB2 receptor, which have been postulated to form 
a disulphide bridge, have been predicted to likely affect the receptors helix conformation rather than 
influence ligand binding directly (160,170). An additional point of note is that the predicted poses 
did not take into account possible hydrogen bonding networks through water molecules in the 
binding site, due to the difficulty in predicting the location of structural waters. As such, based on 
the evidence presented here, we conclude that although predicted binding modes should be treated 
with some degree of caution, our constructed models were found to generally be in agreement with 
experimental data.  
 
3.3.4 Further investigations into the construction of a validated CB1 homology model 
In light of the poorer validation results of our CB1 model in the prediction of binding affinities, 
particularly for CB1 agonists, we attempted to extract and validate further models from our 
molecular dynamics simulations of CB1 using different selection criteria, widening the scope of our 
initial conformational search. 
 Receptor conformations of the CB1 receptor in our MD simulations were first clustered 
using a RMSD tolerance of 0.95Å. The 8 largest clusters, including those formed before protein 
backbone RMSD stabilization, were selected for analysis. The lowest energy conformation and the 
conformation with the lowest average distance to other conformations within the cluster were 
extracted from each of the eight clusters selected. An additional 8 conformations were also 
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extracted randomly from the simulation, bringing the total number of structures to 24. Known 
ligands were then docked into structure in the same validation procedure. 
 While the majority of the structures extracted showed extremely poor correlations between 
experimental and predicted binding affinities, one model (time step of 245.1ns) performed 
reasonably with a R2 value of 0.83 for antagonist ligands. However, correlation for agonist ligands 
was significantly poorer at 0.01, once again highlighting the likelihood of our treatment of the CB1 
receptor with SR141716 in the binding site biasing the simulation towards inactive-state dynamics. 
It was also noteworthy that the simulation time this model was extracted from was similar to our 
previous best-performing model (time step of 240.7ns, R2 of 0.36 for agonists and 0.71 for 
antagonists). Taking into account that the fenofibrate derivatives to be investigated include agonist 
and antagonist ligands, the previously validated model was deemed more suitable for further use. 
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4 STRUCTURE-BASED DESIGN OF NOVEL FENOFIBRATE 
DERIVATIVES AS POTENTIAL CANNABINOID RECEPTOR 
LIGANDS 
4.1 Binding mode prediction of fenofibrate amide derivatives 
A series of fenofibrate amide derivatives, consisting of a mixture of agonists and antagonists with 
varied binding affinities to the cannabinoid receptors, as described in Tables 1-2 and 1-3, was 
docked into our validated models using the procedure described in section 8.1. The lowest energy 
conformations of each derivative obtained from docking were then extracted; applying a consensus 
approach in conjunction with binding affinity and mutagenesis data from literature allowed us to 
determine the most probable binding modes. Analysis of the lowest energy conformations of these 
derivatives at the CB2 receptor in particular yielded a prominent binding mode and key interactions 
supported by pharmacological data, and will therefore be discussed first. 
 
4.1.1 Binding of fenofibrate derivatives to the CB2 receptor 
The binding site for fenofibrate derivatives to the CB2 receptor appeared to be a Y-shaped pocket 
located primarily between TM2, TM3, TM5 and TM6, as shown in Figure 4-1. All ligands docked 
were predicted to bind within this pocket, with an orientation such that the benzophenone moiety 
was located at the bottom of the pocket, while the carboxamide N-substituent resided in either 
branch at the upper end of the pocket. No obvious differences were noted in the predicted binding 
modes of agonists and antagonist derivatives. 
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Figure 4-1 The predicted binding pocket for fenofibrate derivatives in the CB2 receptor 
 
Analysis of the lowest energy poses obtained from the docking of derivatives where 
experimental binding affinities were available revealed one particularly prominent conformation, 
which was adopted by 80% of the most potent compounds (pKi > 7) and 50% of all derivatives with 
good agreement. In this predicted binding mode, the ligands adopted a curved conformation with 
their carboxamide N-substituent directed towards TM3. The excellent overlap between all 
compounds adopting this predicted conformation is shown in Figure 4-2. 
 
Figure 4-2 Overlap between all fenofibrate derivatives predicted to adopt a curved conformation 
when binding to the cannabinoid CB2 receptor. 
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 Visualization of the surrounding residues allowed the identification of possible key 
interactions in maintaining this conformation.  This binding mode and the postulated key 
interactions are shown in Figure 4-3, using a single reference compound 24g as an example. 
 
 
 
Figure 4-3 Predicted binding conformation of fenofibrate derivatives to the CB2 receptor (A), 
along with the key interactions involved (B). The reference structure shown is compound 24g. 
Hydrogen bonds are shown in red dashed lines. Only polar hydrogens are explicitly shown. 
 
 Firstly, in this conformation key hydrogen bonding interactions are formed between the 
carboxamide of each derivative and W5.43, as well as the benzophenone carbonyl with C7.42. 
Mutagenesis studies have recently shown W5.43 to play a critical role in the binding of CP55940, 
WIN55212-2 and SR144528 to the CB2 receptor, further supporting our prediction of a key 
hydrogen bond between fenofibrate derivatives and this residue (171).  On the other hand, C7.42A 
mutation in the CB1 receptor did not affect ligand binding, but labeling of this residue using 
methanethiosulfonate precluded antagonist binding, possibly by introducing steric bulk, indicating 
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that C7.42 may be involved in ligand binding but may not be crucial (184). Although the study did 
not include the equivalent CB2 mutant, the conserved nature of both receptors would suggest that 
by extension, C7.42 may play a role in ligand binding in CB2 or is at least accessible within the 
binding site, as found in our model. Secondly, both benzophenone rings engage in arRPDWLFʌ- ʌ
stacking interactions with F2.57, F3.36 and W6.48. Site-directed mutagenesis data involving W6.48 
in CB2 have shown that it is likely involved in the binding of CP55940 (256). Data for these 
residues in CB1 was also suggestive of their importance, with the binding of SR141716 and 
WIN55212-2 shown to be affected by both F3.36A and W6.48A mutations (167). Furthermore, it is 
widely accepted that the formation of aromatic microdomains play an important role in ligand 
binding at the cannabinoid receptors, reinforced by modeling studies that postulate a F3.36/W6.48 
rotamer toggle switch is involved in receptor activation (154,168). The predicted interaction of 
fenofibrate derivatives with both of these residues was therefore encouraging, although the similar 
poses obtained for both agonist and antagonist derivatives (some of which differed in structure only 
by the position of a single substituent) indicated that our model was unable to capture some of the 
minor intricacies that impart efficacy to these compounds. Thirdly, the carboxamide N-substituent 
of each derivative appeared to reside in a hydrophobic pocket demarcated primarily by F2.64 and 
V3.32, which did not possess any corresponding mutagenesis data. Derivatives with the more 
lipophilic cyclic substituents attached to the carboxamide nitrogen docked more readily into this 
region. Along with interaction of the dimethyl group with I5.47, this indicates that hydrophobic 
contacts with these residues may also be central to maintaining the predicted conformation, which 
is line with previous findings of many potent cannabinoid ligands being high molecular weight 
compounds with substantial hydrophobic character (83,257). Finally, the contrasting presence of 
polar residues such as T3.35 and S3.39 at the bottom of binding pocket was noteworthy, with 
derivatives possessing para substitutions on the benzophenone ring showing the greatest steric 
complement. Pharmacological data of the known fenofibrate amide derivatives showed derivatives 
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with substitutions in the ortho and para positions all displayed some degree of agonism, suggesting 
interaction with these polar residues may play a role in imparting functional activity. 
 $QDOWHUQDWH³H[WHQGHG´FRQIRUPDWLRQZDVDOVRREVHrved, and is shown in Figure 4-4 using 
a different reference compound, though this conformation was less prominent in terms of its 
frequency of occurrence and key interactions involved. The key interactions appeared to be mainly 
a hydrogen bond formed between the carboxamide bond and D5.38 and aromatic stacking of the 
second benzophenone ring with F2.57 and W6.48. 
 
Figure 4-4 AOWHUQDWH ³H[WHQGHG´ FRQIRUPDWLRQ IRU IHQRILEUDWH GHULYDWLYHV ELQGLQJ WR WKH
cannabinoid CB2 receptor. A) Position of extended conformation within the binding pocket. B) Key 
interactions involved in maintaining the extended conformation. The reference compound shown is 
compound 24n. 
 
While we have successfully identified a possible binding mode for fenofibrate derivatives 
to the CB2 receptor, there were inevitably several caveats of note. For one, our model showed no 
significant difference in the binding of agonist and antagonist fenofibrate derivatives as previously 
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highlighted. Secondly, the correlation between experimental pKi values and those predicted by 
docking these derivatives was generally poor, with a corresponding R2 value of 0.16, as almost all 
compounds were predicted to bind with high affinity (pKi > 7). Both these observations are 
attributable to the fact that most of these derivatives are very similar in terms of structure, having 
been based on the same fenofibrate scaffold.  The inherent limitations of current docking programs 
and the protocol chosen, in this case the utilization of grid-based potentials (i.e. docking to a rigid 
receptor), the use of an empirical scoring function, and the standard error in calculating binding free 
energies  (~ 2.5kcal/mol) may have also contributed to these findings.   
 
4.1.2 Binding of fenofibrate derivatives to the CB1 receptor 
In contrast to the CB2
 
receptor, docking of fenofibrate derivatives to the CB1 receptor did not 
produce any particularly prominent conformation. All derivatives bound to a T-shaped binding 
pocket located between TM2, TM3, TM5, TM6, and TM7 (Figure 4-5). As experimental data on 
binding affinity was scarce for the CB1 receptor, all derivatives were taken into account when 
analyzing the conformations extracted. 
 
Figure 4-5 The predicted binding pocket for fenofibrate derivatives in the CB1 receptor 
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The lowest energy conformations of the fenofibrate derivatives did not exhibit any 
prominent consensus in terms of binding mode, and bound in a variety of orientations within the 
binding pocket. Some of these conformations were also deemed improbable, such as those found 
with the ligand protruding out of the helix bundle through the interhelical space between TM3 and 
TM5. Efforts were thus focused mainly on low energy conformations with an orientation such that 
the benzophenone moiety was located at the bottom of the binding pocket, based on previous 
observations with the CB2 receptor. Applying this criterion, the conformation that occurred at the 
highest frequency (75% of derivatives) was found to be a curved conformation similar to that 
observed in the CB2 receptor, but with the carboxamide N-substituent oriented towards TM6 
instead of TM3. Overlap between the derivatives possessing this conformation was found to be 
relatively poor when compared to the predicted binding mode in the CB2 receptor (Figure 4-6). 
 
 
 
Figure 4-6 Overlap between all fenofibrate derivatives predicted to adopt a curved conformation 
when binding to the cannabinoid CB1 receptor. 
 
 
 
95 
 
This binding conformation and the key interactions involved in this conformation are 
shown in Figure 4-7. The carboxamide N-substituent of the fenofibrate derivatives were once again 
placed in a hydrophobic pocket, which in CB1 were formed by residues F5.42, W6.48, L6.51, 
L6.52 and M6.55. For the residues L6.51, L6.52 and M6.55, the corresponding CB2 residues have 
been shown to be on the solvent-accessible surface in the binding site crevice, suggesting that their 
position in CB1 is likely to be similar (252). Site-directed mutagenesis studies have also shown 
W6.48 to play a role in SR141716A and WIN55212-2 binding (167). The carboxamide group did 
not appear to make any specific interactions, while the dimethyl group was found to interact mainly 
with V3.32 and T3.33. The only other interactions of note were between the benzophenone 
carbonyl and W6.48, and aromatic stacking of the second benzophenone ring with F2.57. The 
residue F3.36, which was also linked to SR141716A and WIN55212-2 binding, interactions 
between ligand and residue appeared to be non-specific in nature (167). The bottom of the binding 
pocket was found to be also predominantly polar in nature, formed mainly by D2.50, S3.39, N7.45, 
and S7.46. Overall, while this constitutes key interactions and a possible binding mode for 
fenofibrate derivatives to the CB1 receptor, the lack of a defined orientation for the derivatives, 
poor overlap between derivatives predicted to adopt this conformation, and limited support from 
site-directed mutagenesis studies indicated that these findings should be at the very least treated 
with some degree of caution.  
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Figure 4-7 Predicted binding conformation of fenofibrate derivatives to the CB1 receptor (A), 
along with the key interactions involved (B). The reference compound shown is 24h. Only polar 
hydrogens have been explicitly shown. 
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4.2 Structure-based design of novel ligands potentially binding to the 
CB2 receptor  
 
 In light of these findings and taking into consideration the robustness of the binding mode 
predictions for both receptors, efforts in designing novel ligands were focused primarily on the CB2 
receptor. Utilizing compound 24g as a lead, modifications were made to the ligand in order to 
increase the complement between ligand and receptor whilst maintaining the predicted binding 
mode and key interactions. Specifically, compound 24g was revised with a view to: 
x Increase the hydrophobic bulk of the carboxamide N-substituent using cyclic moieties 
x Increase the polarity and hydrogen-bonding capacity of the 4-substituted benzophenone in 
order to complement the polar region of the binding pocket. 
x Reduce loss of configurational entropy upon binding by rigidifying derivatives in the 
predicted conformation 
A series of compounds was thus derived using these strategies and were subsequently modelled and 
docked into the validated CB2 receptor model using the previously established protocol. The final 
series of compounds selected for synthesis was made following assessment of their ability to allow 
for a detailed evaluation of the binding mode hypothesis and the structure-based design strategies 
employed, ease of synthesis, and the commercial availability of starting materials; this selection is 
shown in Table 4-2 and Figure 4-8. 
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Table 4-2 Novel fenofibrate derivatives selected for synthesis and pharmacological evaluation. 
Derivatives were designed with an aim to increase the hydrophobic bulk of the carboxamide N-
substituent with cyclic moieties and to increase polarity in the benzophenone 4-position. 
 
No R1 R2 
30a Cl 
 
exo-norborn-2-yl 
30b Cl 
 
R(+)-born-2-yl 
30c Cl 
 
adamant-1-yl 
31a CF3 
 
piperidin-1-yl 
31b CF3 
 
exo-norborn-2-yl 
31c CF3 
 
R(+)-born-2-yl 
31d CF3 
 
adamant-1-yl 
32a OH 
 
piperidin-1-yl 
32b OH 
 
exo-norborn-2-yl 
32c OH 
 
R(+)-born-2-yl 
32d OH 
 
adamant-1-yl 
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Figure 4-8 Novel maleimide derivative designed to reduce loss of conformational entropy upon 
binding to the CB2 receptor.  
 
  
Figure 4-9 illustrates the predicted binding of several of these compounds when compared 
to reference compound 24g. The piperidinyl and norbornyl compounds (30a, 31a, 32a-b), with the 
exception of 31b, were all predicted to maintain the binding conformation and the associated key 
interactions. Conversely, the bornyl and adamantly derivatives (30b-c, 31c-d, 32c-d) did not bind 
similarly, only accessed the predicted binding mode at higher energy levels, and even then were 
frequently unable to maintain key hydrogen bonds with W5.43 and C7.42. Nevertheless these 
compounds were still selected for synthesis and pharmacological evaluation, as previous work by 
Pasquini et al. and Baraldi et al. have shown the carboxamide-adamantyl moiety to be 
advantageous in developing potent CB2-selective agonists (115,116).  The inclusion of these 
compounds would also serve to highlight the importance of some degree of leniency, expert 
intervention, or the utilization of a consensus approach in interpreting the docking results obtained, 
particularly since a rigid receptor model was employed. 
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Figure 4-9 Predicted binding conformation of 30a (cyan), 31a (magenta), 30b (yellow), 32d 
(purple) and 33 (brown) in reference to 24g (green). 
 
Compound 33 was also of particular interest, as fusion of the amide bond and dimethyl 
ether linkage into a maleimide ring did not affect the predicted binding mode when this compound 
was docked into our CB2 model. The amide bond is a consistent feature of many prominent CB1
 
and CB2 ligands, particularly when coupled to a group with high hydrophobicity, as seen in 
SR141716A, SR144528, GW842166X, and previously described CB2 selective 4-quinolone-3-
carboxylic acid, oxazinoquinolone, and heteroarylpyridine/ heteroarylpyrimidine derivatives (115±
117). The synthesis and pharmacological characterization of 33 would not only represent a 
successful case of structure-based design providing a new scaffold for the derivation for further 
structure-activity relationships, but would also lend further support to the hypothesized binding 
mode due to its reduced structural flexibility and propensity to adopt the predicted conformation.  
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5 SYNTHESIS OF NOVEL FENOFIBRATE DERIVATIVES AS 
POTENTIAL CB2 RECEPTOR LIGANDS 
5.1 Synthesis of novel amide derivatives of fenofibrate 
 
Scheme 1 Synthesis of fenofibrate derivatives 30a to 32d. Reagents and conditions: i) AlCl3, 
anisole, DCM, N2, 24h; ii) Pyridine.HCl, microwave irradiation, 16 min; iii) Methyl-2-
hydroxyisobutyrate, PPh3, DIAD, N2, MeCN, reflux, 15h; iv) NaOH, THF/water 1:1, 6-24h; v) 
Selected amine, Et3N, HBTU, 4-24h 
 
The synthesis of the novel compounds designed retaining the original fenofibrate amide scaffold 
was achieved as outlined in Scheme 1. The synthetic route employed had previously been 
demonstrated to be successful in the synthesis of other fenofibrate amide derivatives (179). Starting 
from the commercially available 4-substituted benzoyl chlorides (34a,b), these were reacted with 
anisole in the presence of AlCl3, under standard Friedel-Crafts conditions to produce the required 
¶
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would therefore be expected to be both 2- and 4-directing in electrophilic aromatic substitution, the 
desired ¶-disubstituted benzophenone isomers 35a,b was obtained in good yield (~80%) in both 
cases, likely due to steric effects hindering substitution at the 2-position.  
 
Subsequent demethylation of aryl methyl ether using more conventional methods (BBr3 in 
DCM) have been previously shown to be unsuccessful, and as such was achieved via neat 
microwave irradiation in the presence of pyridine hydrochloride as first demonstrated by Kulkarni 
et al (179,258). Yields were inconsistent when the reaction was conducted in a conventional 
microwave oven at constant power of 220W as espoused by the original study. Utilization of a 
specialized microwave reactor at variable power and constant temperature subsequently improved 
reaction efficiency. It was noteworthy that while reaction temperatures were initially selected solely 
based on the melting point of the substituted benzophenone in order to allow mixing with pyridine 
hydrochloride, there appeared to be a critical temperature for the reaction to progress that was 
independent of the melting point of the reactant and microwave power. This observation was 
consistent with the findings of studies attributing the contribution of microwave irradiation to 
accelerate certain reactions to be completely thermal in nature (259). 4,4¶-Dihydroxybenzophenone 
(36c) was obtained commercially. 
 
Alkylation of the exposed phenol through Williamson ether synthesis to generate the 
required fenofibric acid derivatives, although previously demonstrated by Spencer et al (179), 
proved to be unsuccessful, and can be attributed to the tertiary nature of the alkyl halide required in 
the reaction precluding effective SN2 nucleophilic substitution. Consequently, syntheses of the 
corresponding methoxy esters 37a-c were achieved using a variant of the Mitsunobu reaction (with 
DIAD and triphenylphosphine) at elevated temperatures of 80-100°C that has been previously 
shown to be successful in the synthesis of tertiary alkyl-aryl ethers (260). Due to solubility issues, 
the solvent was changed from toluene in the original study to acetonitrile, and the reaction was 
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conducted under reflux. The reaction gave moderate yields of 50-70% following purification for the 
halogenated derivatives 37a,b but was poorer (~30%) for the hydroxyl substituted derivative 37c;  
this resulting from the formation of the disubstituted alkyl-aryl ether and difficulty in purification 
owing to the product possessing a Rf similar to that of reduced DIAD from the reaction. Cleavage 
of the methoxy ester in base-catalysed ester hydrolysis then afforded fenofibric acid 22 or its 
derivatives 38a,b.  
 
The final desired compounds 30a-32d were then obtained via amide coupling between the 
fenofibric acid derivative and the corresponding amine using HBTU in the presence of 
triethylamine. Excellent yields (> 90%) were once obtained for the halogenated derivatives 30a-31d 
but was poorer (~30%) for the hydroxyl derivatives 32a-d.  Following purification using a 
combination of radial thin layer chromatography and recrystallization, the structures of the final 
compounds were confirmed using NMR, FTIR, and HRMS, while purity of 95% or higher was 
confirmed using analytical HPLC.    
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5.2 Synthesis of a novel maleimide derivative of fenofibrate 
 
 
Scheme 2 Synthesis of fenofibrate maleimide derivative 33. Reagents and conditions: i) propionic 
anhydride, TiCl4, n-Bu3N, DCE, reflux, 12h; ii) exo-2-aminonorbornane, HMDS, ZnI2, toluene, 
reflux, 3.5h; iii) 4-chlorobenzoyl chloride, AlCl3, DCM, r.t. 
The synthesis of the novel maleimide derivative of fenofibrate 33 was attempted using the synthetic 
route shown in Scheme 2. As previously demonstrated by Kishorebabu et al (261), 2-methyl-3-
phenylmaleic anhydride 40 was synthesized from ethyl benzoylformate and propionic anhydride 
using a titanium (IV) chloride/tributylamine system.  Despite identical reaction conditions, the yield 
obtained was significantly lower than that reported in the original study (28% vs 81%). Conversion 
of the maleic anhydride to a maleimide and coupling of norbornyl moiety was achieved in a single 
step using the method shown by Reddy et al (262), with ZnI2 as a Lewis acid and 1,1,1,3,3,3-
hexamethyldisilazane (HMDS), giving the maleimide 41 in an excellent yield of 86%. 
 Subsequently, we attempted to synthesize 33 from 41 using the same classic Friedel Crafts 
conditions that were previously successful in the synthesis of substituted benzophenones. This 
proved unsuccessful, with no reaction progress recorded even after doubling the reaction time to 48 
hours. This observation could possibly be attributed to the highly conjugated nature of the 
maleimide deactivating the aryl via electron delocalization, precluding nucleophilic attack on the 
acylium ion intermediate. As such, we attempted to utilize variations of the Friedel Crafts reaction 
that have been shown to be more efficient and effective even on deactivated systems. Microwave 
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irradiation in the presence of zinc powder (263) produced several products, none of which showed a 
mass/charge ratio consistent with the desired product in HRMS analysis. A neat reaction with zinc 
oxide, which has been previously shown to be effective even with highly deactivated compounds 
such as nitrobenzene (264), was also unsuccessful with no reaction progress recorded. At the time 
of writing the synthesis 33 was incomplete, and will be discussed in future publications.  
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6 PHARMACOLOGICAL EVALUATION OF NOVEL 
FENOFIBRATE DERIVATIVES AT THE CB2 RECEPTOR 
6.1 [3H]CP55940 competition binding assay and [356@*73Ȗ6 ELQGLQJ
assay 
Compounds 30a-32d (Table 4-2) were assayed for binding affinity and functional activity at the 
human CB2 cannabinoid receptor. Binding affinity was determined in a competition binding assay 
using [3H]CP55940 as the radioligand. Efficacy was determined using the [356@ *73Ȗ6 ELQGLQJ
assay. All assays were conducted using membrane homogenates of CHO cells transfected with 
recombinant human CB2 receptors, using the same protocol as Spencer et al (179) to ensure 
consistency and comparability of results, with the exception that full response curves were 
generated for the functional assay. The results of this assay were additionally expressed as a 
percentage of the maximum response achievable to provide an indication of the degree of agonist 
response obtained, which was indeterminable from the study by Spencer et al. The results of both 
assays are presented in Tables 6-1. 
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No R1 R2 pKi  at CB2 
a % Maximal 
displacement 
% CB2 activation 
at 10 ȝM pEC50/pIC50
b 
Emax (%) 
b 
30a 4-Cl exo-norborn-2-yl 7.20 ± 0.05 96 ± 1        235 ± 41 7.50 ± 0.14  68 ± 3 
30b 4-Cl R-(+)-born-2-yl 6.06 ± 0.12* 40 ± 5          45 ± 4 5.72 ± 0.10 -55 ± 12 
30c 4-Cl adamant-1-yl 6.38 ± 0.02* 70 ± 3          76 ± 2 5.82 ± 0.09 -24 ± 3 
31a 4-CF3 piperidin-1-yl 6.93 ± 0.13 96 ± 2         282 ± 6 7.34 ± 0.04  90 ± 1 
31b 4-CF3 exo-norborn-2-yl 6.58 ± 0.05 83 ± 6         145 ± 8 7.05 ± 0.05  25 ± 0 
31c 4-CF3 R-(+)-born-2-yl 6.38 ± 0.12* 45 ± 5           59 ± 7 6.13 ± 0.13 -23 ± 6 
31d 4-CF3 adamant-1-yl 7.04 ± 0.16* 49 ± 5            60 ± 11 6.78 ± 0.11 -27 ± 7 
32a 4-OH piperidin-1-yl 6.63 ± 0.10 99 ± 8         282 ± 48 6.94 ± 0.09  94 ± 5 
32b 4-OH exo-norborn-2-yl 6.01 ± 0.03 107 ± 2         301 ± 80 6.51 ± 0.13  80 ± 4 
32c 4-OH R-(+)-born-2-yl 5.26 ± 0.07* 46 ± 9           84 ± 3 - c       - c 
32d 4-OH adamant-1-yl 5.72 ± 0.05* 56 ± 2         133 ± 4 7.06 ± 0.15  21 ±2 
Table 6-1 Binding affinity and efficacy of compounds designed based on modelling data at the CB2 receptor. Data represent mean values 
± SEM of three independent experiments. a Displacement of [3H]CP55940 in membrane homogenates of CHO cells transfected with 
human CB2 receptors over 10 concentration values; binding affinities (pKi) were determined using experimental IC50 values and the 
Cheng-Prusoff equation.  b Measurement of enhancement of [356@*73Ȗ6ELQGLQJDVVD\HGRYHUFRQFHQWUDWLRQVYDOXHV(max is expressed 
as a percentage of the maximum agonist-enhanced response, which was defined as the response elicited by 1µM CP55940 under identical 
conditions. c Not converged. * Apparent pKi; compounds displayed only partial displacement of [3H]CP55940. 
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Compounds 30a, 31a-b, and 32a-b were all able to displace [3H]CP55940 completely (with 
the exception of 31b which showed near-full (83%) displacement) in the competition binding assay 
and showed binding affinities (pKi) of 7.20, 6.93, 6.58, 6.63, and 6.01 respectively.  Compounds 
30b-c, 31c-d, and 32c-d were not able to displace [3H]CP55940 completely even at high 
concentrations; their apparent binding affinities (pKi) were 6.06, 6.38, 6.38, 7.04, 5.26, and 5.72 
respectively. In the [356@*73Ȗ6ELQGLQJDVVD\compounds 30a, 31a-b, and 32a-b, d all showed 
agonist activity with Emax values of 68%, 90%, 25%, 94%, 80%, and 21% respectively. Compounds 
30b-c and 31c-d showed inverse agonist activity with Emax values of -55%, -24%, -23%, and -27% 
respectively. Only compound 32c showed neutral antagonist activity. 
The piperidinyl and norbornyl derivatives 30a, 31a-b, and 32a-b all showed moderate to 
good CB2 receptor affinity in the nanomolar range. Affinity of the norbornyl derivatives were all 
slightly lower compared to their piperidinyl counterparts, while in both cases affinity decreased 
depending on the benzophenone 4-substituent in the order of Cl > CF3 > OH, which was roughly in 
line with modelling data (predicted binding affinities were in the order of Cl > CF3 = OH). This 
effect of the N-substituent could once again be attributed to steric factors, although the lack of N-N 
functionality in the norbornyl analogues affecting electronic distribution of the amide and 
hydrogen-bonding capacity cannot be ruled out. The effect of the benzophenone substitution on 
affinity was less clear; in general it seems that increasingly polar 4-substituents have a detrimental 
effect on binding. Functionally, the compounds 30a, 31a, and 32a-b demonstrated a level of agonist 
activity significantly higher (% activation above basal of 235, 282, 282, and 301 respectively) than 
the compounds presented by Spencer et al (179). It was noteworthy that 31a and 32a-b were able to 
elicit a response comparable to that of the full agonist CP55940, an effect in line with our 
modelling predictions that ligand interaction, particularly hydrogen bonding, with polar residues 
such as T3.35 and S3.39 at the bottom of the binding pocket may play a role in the functional 
response of the CB2 receptor towards these derivatives. 
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Increasing hydrophobic bulk of the carboxamide N-substituent further had an intriguing 
effect on the pharmacology of these derivatives. The bornyl and adamantyl compounds 30b-c, 31c-
d, and 32c-d exhibited saturable but incomplete displacement of [3H]CP55940, indicating that these 
compounds were  likely binding to a site distinct from the orthosteric site occupied by CP55940. As 
the Cheng-Prusoff equation assumes both the competing ligand and the radioligand bind 
exclusively to the same site, the apparent pKi values of these compounds do not provide a true 
indication of their binding affinities.  Figure 6-1 shows the predicted binding of CP55940 in 
relation to our previously predicted binding mode of fenofibrate amide derivatives. The functional 
activity of these compounds shifted in tandem with their binding, as 30b-c and 31c-d were clear 
inverse agonists while 32c-d showed neutral antagonist and partial agonist characteristics 
respectively. This shift towards allosteric binding and functional activity with increasing 
hydrophobic bulk of the carboxamide substituent is illustrated in Figure 6-2 with compounds 31a-d 
(see Appendix VI for figures of other compounds in this series). 
 
 
Figure 6-1 Predicted binding mode of CP55940 (grey) in reference to compound 24g (green). 
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Figure 6-2 Pharmacology of several novel fenofibrate derivatives displaying a shift from 
orthosteric to allosteric binding. (A) Displacement of [3H]CP55940 from membrane homogenates of 
CHO cells expressing the human CB2 receptor. (B) Measurement of enhancement of [35S]GTPȖ6
binding in membrane homogenates of CHO cells expressing the CB2 receptor, expressed as a 
percentage of the response achieved by 1µM CP55940. The figures represent the means ± SEMs of 
three independent experiments. 
 
111 
 
 As our model had predicted that the bornyl and adamantyl derivatives were unable to adopt 
the same binding conformation as other fenofibrate derivatives, these findings lend credence to our 
modelling data, supporting the hypothesis that maintaining key hydrogen bonds with W5.43 and 
C7.42 as well as aromatic stacking interactions with F2.57, F3.36 and W6.48 appear crucial in 
stabilizing the binding of fenofibrate derivatives to the orthosteric site. Although hydrophobic 
cyclic carboxamide N-substituents were shown to be favourable in CB2 receptor binding, past a 
certain limit steric constraints appear to impair the ability of the ligand to maintain these key 
interactions, resulting in allosteric binding. The loss of this binding mode would also preclude 
interaction of the R1 4-substituent with aforementioned polar residues such as T3.35 and S3.39 that 
may influence receptor activation, evidenced by the primarily inverse agonist nature of these 
allosteric binders. In the absence of more pharmacological data we can only speculate on the exact 
nature and location of this allosteric site, although the gradual shift in binding and activity with 
increasing hydrophobic bulk of the carboxamide substituent suggests a possible partial overlap with 
the orthosteric region. Such a manner of binding would be analogous to that of the CB1 allosteric 
modulator ORG27569 42, whose allosteric binding site in CB1 has recently been deduced to 
overlap partially with that of the orthosteric binder SR141716 (265). However, the development of 
these compounds together with additional investigations into their pharmacology is warranted 
before any concrete conclusions can be made.  
 
Figure 6-3 Structure of ORG27569 
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The fenofibrate derivatives 30a-32d presented here represent a novel set of CB2 receptor 
ligands, ranging from orthosteric binders with high CB2 receptor affinity and agonist activity to 
allosteric binders with inverse agonist activity. The observed shift from orthosteric to allosteric 
binding with increasing cyclic hydrophobic bulk of the carboxamide N-substituent demonstrated 
here represents a unique and interesting structure-activity relationship not previously seen in 
fenofibrate derivatives binding to the CB2 receptor, and to the best of our knowledge, in other CB2 
ligand series. The pharmacology of these derivatives also provides experimental evidence of our 
modelling predictions, demonstrating that the binding mode of fenofibrate derivatives to the CB2 
receptor is indeed likely to be stabilized primarily by hydrogen bonds with W5.43 and C7.42 in 
addition to aromatic stacking with F2.57, F3.36 and W6.48. These findings also serve to validate 
our modelling protocols, demonstrating that the selection of a CB2 homology receptor model from 
a molecular dynamics-refined ensemble and its subsequent validation resulted in a model with 
significant predictive capability that can be used for the design of novel ligands. The model and 
binding mode predictions presented here may therefore serve as useful predictive tools in future 
CB2 receptor investigations, particularly in the design of novel fenofibrate amide derivatives as 
CB2 ligands.  
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7 CONCLUSIONS AND FUTURE WORK 
7.1 Conclusions 
7.1.1 Molecular modelling of the CB1 and CB2 receptors 
 We have presented here the construction of homology models of the human CB1 and CB2 
cannabinoid receptors based on the crystal structure of the human adenosine A2A receptor. 
Molecular dynamics simulations of the receptors within a POPC bilayer have allowed us to refine 
both models and produce an ensemble of structures for model validation. While the CB2 receptor 
model remained stable throughout our simulations, the closure of the CB1 binding site was 
problematic and necessitated that we simulate the receptor with the known antagonist SR141716 
bound. 
 Both simulations provided models that performed well in validation tests that included the 
binding affinity prediction of known ligands, virtual screening exercises, and the binding mode 
assessment of well-characterized ligands in conjunction with mutagenesis data. As expected the 
CB2 receptor model performed better in these validation tests particularly when considering agonist 
ligands, a likely consequence of our treatment of the CB1 receptor during MD simulations. 
Nevertheless, we have demonstrated that MD simulations remain a viable option in the refinement 
of cannabinoid receptor homology models. These cannabinoid receptor models represent potential 
tools in computational drug design applications beyond those presented here. 
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7.1.2 Structure-based design of novel fenofibrate derivatives as CB2 receptor ligands 
The binding mode of fenofibrate amide derivatives with known cannabinoid receptor activity have 
been predicted here by the docking of these derivatives into both validated models. Predictions for 
the CB2 receptor were particularly robust following comparison with mutagenesis data, showing a 
binding mode stabilized by hydrogen-bonds with W5.43 and C7.42, aromatic stacking with F2.57, 
F3.36 and W6.48, and hydrophobic contacts with F2.64, V3.32 and I5.47. The contrasting presence 
of polar residues T3.35 and S3.39 at the bottom of the binding pocket was also of note, suggesting 
interaction with residues may impart functional activity. In light of these findings a series of 
compounds designed to test this binding hypothesis (30a-32d) were modelled and docked into our 
CB2 receptor model before being synthesized and pharmacologically evaluated. 
 The pharmacology of these newly designed derivatives provided evidence supporting our 
modelling predictions, allowed for the elucidation of further structure-activity relationships, and 
resulted in the discovery of novel allosteric CB2 receptor binders.  With a gradual increase in 
hydrophobic bulk of the carboxamide N-substituent, the compounds demonstrated a shift from 
orthosteric to allosteric binding, validating our predicted binding mode as the compounds with 
highly hydrophobic (bornyl and adamantyl) carboxamide N-substituents were predicted to be 
unable to maintain the binding mode and key interactions, particularly hydrogen bonding with 
W5.43 and C7.42. These novel allosteric binders also showed primarily inverse agonist activity in 
contrast to the agonist orthosteric binders. Increasing the polarity and hydrogen bonding capacity of 
the R1 4- substituent lowered CB2 binding affinity, but resulted in compounds with efficacies 
significantly higher than previously reported fenofibrate derivatives and comparable with that of the 
full agonist CP55940, supporting the hypothesis that the polar residues at the bottom of the binding 
pocket may influence receptor activation.   
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 In conclusion, we have demonstrated here the successful use of a molecular dynamics-
refined homology model of the human CB2 cannabinoid receptor in the structure-based design of 
novel ligands based on the fenofibrate scaffold. We have predicted the binding mode and the 
associated key interactions of this class of ligands, and validated these predictions by the 
prospective design of novel derivatives, which also provided further insight into the structure 
activity relationships governing their binding and efficacy. In addition, we have discovered several 
novel CB2 allosteric binders that demonstrate pharmacology distinct from other fenofibrate 
derivatives. These findings may be used to guide the design of further derivatives, and highlight the 
promise of the fenofibrate scaffold in developing novel CB2 receptor ligands. 
 
7.2 Future Work 
7.2.1 Molecular modelling of the CB1 and CB2 receptors 
While the CB1 and CB2 cannabinoid receptor models constructed here have proven useful, there 
were inevitably several limitations to their predictive ability. In the context of our CB2 receptor 
model and fenofibrate derivatives, correlation between predicted and experimental binding 
affinities remained low due to the similarity between derivatives. This model can thus be used to 
predict the likelihood of a ligand maintaining key interactions and the relative binding affinity 
between derivatives, but in efforts to design increasingly potent ligands a higher degree of accuracy 
would be welcome. As the binding mode of these derivatives have been predicted with some 
confidence here, the application of other scoring functions or consensus scoring may provide the 
predictive ability desired, although the inherent limitations of current scoring functions have been 
highlighted earlier. 
 Our CB1 receptor model did not provide predictions that were highly supported by 
mutagenesis data, and in the absence of the equivalent CB1 pharmacological data for the novel 
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derivatives described here we make no claims on the accuracy of the predicted binding mode. 
However, the closing of the CB1 binding site during MD simulations, observed unwinding of the 
alpha helices, subsequent simulations with SR141716 bound, and positioning of certain key 
residues such W5.43 towards the lipid bilayer remain causes of concern. Efforts to resolve such 
issues may include MD simulations with different force fields such as the GROMOS 54a7, 
CHARMM and AMBER force fields (138,139,266). Studies on the dynamics of the receptor under 
such conditions using techniques such as principal component analysis may provide insight into our 
observations here and enhance the findings of previous studies into GPCR dynamics done by our 
group (267,268). Preliminary work in simulating the apo-CB1 receptor using the GROMOS 54a7 
force field has shown that while this results in increased alpha helix stability as expected (the 54a7 
set was parameterized to address this occurrence), the CB1 receptor binding site still closed during 
MD simulation. The final construction of a validated CB1 receptor model would provide an 
additional tool in the rational design of novel cannabinoid receptor ligands based on the fenofibrate 
scaffold, allowing for the prediction of properties such as CB2/CB1 receptor selectivity. 
 
7.2.2 Chemistry and structure-based design of further novel ligands 
Although the derivatives 30a-32d have validated our binding mode predictions, the successful 
synthesis of the fenofibrate maleimide derivative 33 would represent the derivation of a novel 
scaffold for CB2 cannabinoid receptor ligand development. As it appears that the synthetic route 
employed in Scheme 2, specifically Friedel-Crafts reaction of the 3-phenylmaleimide 41 is unlikely 
to yield positive results, alternative synthetic routes would have to be employed. One possible 
scheme is shown below in Scheme 3, employing Weinreb ketone synthesis instead of a Friedel-
Crafts reaction, although the stability of 43 in the titanium (IV) chloride/n-tributylamine system and 
the stability of Grignard reagent 46 would be a cause of concern. 
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Scheme 3 Possible alternative synthesis of fenofibrate maleimide derivative 33. Reagents and 
conditions: i) propionic anhydride, TiCl4, n-Bu3N, DCE, reflux, 12h; ii) exo-2-aminonorbornane, 
HMDS, ZnI2, toluene, reflux, 3.5h; iii) Mg, Et2O, reflux; iv) THF, 0°C. 
 
 The structure-activity relationships derived here also present the opportunity for the 
development of further derivatives based on the fenofibrate scaffold. Specifically, the introduction 
of other bulky heterocyclic substituents at the carboxamide such as piperazine, indole, and 
quinolone motifs combined with polar substituents at the R1 4-position may represent potential 
potent CB2 agonists. These derivatives could be docked into our CB2 model in order to ease the 
selection process. Simultaneously, the synthesis of further adamantyl, bornyl and equivalent 
derivatives as allosteric binders would allow for more detailed investigations into their structure-
activity relationships, ideally culminating in the identification of their allosteric binding site and an 
equivalent binding mode prediction based on the same consensus approach applied here. 
118 
 
 
Figure 7-1 Potential CB2 cannabinoid receptor ligands based on the fenofibrate scaffold 
investigating orthosteric (48) and allosteric (49) structure-activity relationships. 
 
7.2.2 Pharmacology 
In the context of the novel CB2 receptor ligands described here, the pharmacology of the 
orthosteric and allosteric binders described here may both be subject to further investigations. 
While the predicted binding mode of the orthosteric binders already possesses strong support from 
the pharmacological data available, short of crystallographic data, site-directed mutagenesis studies 
involving the key residues implicated in their binding such as W5.43, C7.42, F3.36 and W6.48 
would provide unequivocal proof of their binding mode. In the same manner mutagenesis studies 
would be beneficial in the investigation of the allosteric binders by alluding to their possible 
binding site, although more thorough investigations are warranted as the literature regarding CB2 
allosteric binding is by far less extensive. A more pertinent line of inquiry would be to describe the 
allosteric modulation properties of these derivatives on the binding of orthosteric ligands, if any, 
through assays such as binding kinetics assays. 
 In a typical dissociation kinetic assay the dissociation rate of a radioligand (e.g. 
[3H]CP55940) is measured by first allowing the radiolabelled ligand  to achieve equilibrium with 
the receptor, and then initiating dissociation by either diluting the sample or adding an excess of 
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unlabelled competing compound. The specific binding of the radioligand is then measured at 
several time points following this, allowing the dissociation pattern of the radioligand to be plotted 
and dissociation rate constants to be calculated (269). In the presence of allosteric modulators, this 
dissociation rate is altered, with positive allosteric modulators decreasing the dissociation rate and 
negative allosteric modulators increasing the dissociation rate of the radioligand. Conducting assays 
such as this would provide definite evidence of any potential modulatory properties of the allosteric 
compounds described here.          
 CB1 pharmacological data (particularly CB1 receptor binding affinity data) of the novel 
derivatives designed based on our modelling data in addition to those previously described by 
Spencer et al (179) would provide additional experimental input into our modelling predictions and 
allow us to establish more concrete structure-activity relationships than those currently available. 
Such data would be highly valuable in achieving our final goal of constructing validated models of 
both cannabinoid receptors for structure-based drug design. 
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8 EXPERIMENTAL 
8.1 Molecular modelling 
All calculations were performed on a Linux cluster consisting of 72 Intel Xeon 3.12 GHz 
processors. Energy minimizations and molecular dynamics simulations were conducted using the 
GROMACS software suite with the GROMOS 53a6 united-atom force field, supplemented with 
additional lipid parameters (140,270). Full periodic boundary conditions were applied. The simple 
point charge (SPC) water model was used (271). The maximum force tolerance for energy 
minimization was set at 10kJ/mol/nm. The time step used was 2fs. Cut-offs for short-range 
electrostatic and van der Waals (vdW) interactions were set at 14Å at 10Å respectively. Long range 
electrostatic interactions were treated using the Particle Mesh Ewald method (272,273). The 
neighbour list cut-off was set at 10Å and updated every 5 steps. All bonds lengths were constrained 
using LINCS, while SETTLE was used to constrain the geometry of water molecules (274,275). 
Temperature coupling at 310K was achievHGXVLQJYHORFLW\UHVFDOLQJZLWKDFRXSOLQJFRQVWDQWRIĲ
= 0.5ps (276). Semi-isotropic pressure coupling at 1 bar was achieved using the Parinello-Rahman 
EDURVWDWZLWKDFRXSOLQJFRQVWDQWRIĲ SV(277). 
All docking was conducted using AUTODOCK 4.2 with a Lamarckian genetic algorithm 
(278,279). Ligands were  initially constructed and subsequently energy minimized using 
ChemBioDraw Ultra 12.0 (280). The ligands and protein structures were then assigned Gasteiger 
charges and prepared for docking using AutoDock Tools (279). All torsions in ligands were 
assigned as flexible, while the receptor itself was kept rigid. 100 runs were conducted for each 
ligand. Population size was set at 300 for each run, while maximum number of evaluations was set 
at 2,500,000, and maximum number of generations set at 27,000. Grid spacing of 0.2Å was used. 
Cluster analysis was done using an RMSD tolerance of 1.0Å. Predicted pKi values were extracted 
for the conformations with the lowest binding energies. 
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8.2 General chemistry 
All chemicals and solvents were bought from standard suppliers and were used without further 
purification. Anhydrous solvents were prepared using 3Å molecular sieves (3-4 mesh, Sigma 
Aldrich) according to the method presented by Williams et al (281).  
All reactions were conducted under ambient temperatures unless otherwise stated. Reactions 
monitored using thin layer chromatography were done using commercially available pre-coated 
aluminium backed plates from Merck (Merck TLC Silica Gel 60 F254, Product No HX273866), 
with visualization under standard UV wavelengths (254 and 366nm). All purifications using 
centrifugal radial TLC were conducted using a Harrison 7924T Chromatotron, with the sorbent 
layer prepared using Merck Silica Gel 60 PF254 containing gypsum (Product No TA1762549). 
Column chromatography was performed using Merck silica gel 60, 230-400 mesh (Product No 
TA1686285). All microwave reactions were carried out using either a Sharp R-658L(S) 800W 
Microwave Oven or a CEM Discover Series Microwave Reactor. All compounds were identified 
and characterized using a combination of NMR, HRMS, and FTIR. All melting points were 
recorded using a Stuart SMP10 Melting Point Apparatus and are uncorrected. Melting points for 
compounds were compared using data obtained from the ChemSpider database where available 
(282). FT-IR spectra were recorded using a Perkin Elmer Spectrum RX1 FTIR Spectrophotometer 
as KBr discs or thin films, with a range of 4000-400cm-1. 1H and 13C NMR spectra were recorded in 
appropriate deuterated solvents using a Bruker 400 or 600 MHz spectrometer. Chemical shifts are 
reported relative to an internal reference of tetramethylsilane at 0.00ppm. Positive electrospray 
ionization (ESI) high resolution mass spectroscopy was obtained using a JMS-T100LP DART-TOF 
mass spectrometer. The final compounds were determined to be of at least 95% purity through 
analytical HPLC, using a Perkin Elmer Series 200 HPLC system with a 4.6 x 250mm Agilent 
Zobrax 300SB-C18 column.    
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All organic extracts following aqueous work-up were dried using either anhydrous Na2SO4 or 
anhydrous MgSO4, filtered via gravity or vacuum filtration, and the solvent removed under reduced 
pressure with temperatures less than 40°C using a rotary evaporator. 
8.2.1 General methods 
Unless otherwise stated, all reactions were carried out using the following General Methods: 
General Method A: Adapted from reference (179). To anhydrous AlCl3 (1.1eq) under a N2 
atmosphere, 20mL of anhydrous DCM was added. Anisole (1.0 eq) was then added, and the 
reaction mixture cooled to 0°C in an ice bath. The selected benzoyl chloride (1.0 eq) was then 
added dropwise. The reaction mixture was kept at 0°C for 30 minutes before being slowly brought 
to room temperature and stirred overnight. The reaction mixture was then quenched using a 20mL 
mixture of ice and 2M HCl, and the aqueous layer extracted using DCM. The combined organic 
layers were then washed with water (twice) and brine, before being dried over anhydrous Na2SO4 
and the solvent removed under vacuum. 
General Method B: Adapted from reference (258). (1) For reactions conducted using a standard 
microwave oven: A mixture of the selected 4-methoxybenzophenone (1.0eq) and pyridine 
hydrochloride (5.0eq) were mixed in either a stoppered round bottom flask and irradiated at 240W 
for 16 minutes in 2 minute intervals, with the flask being cooled to room temperature in between 
cycles. (2) For reactions conducted using a microwave reactor: A mixture of the selected 4-
methoxybenzophenone (1.0eq) and pyridine hydrochloride (5.0eq) were mixed in a microwave vial 
and irradiated at variable power and 200°C for 16 minutes. 
The reaction mixture was then quenched using 20mL of ice water, and extracted with ethyl acetate. 
The organic layer was then washed with brine, dried over anhydrous Na2SO4, and the solvent 
removed under vacuum. 
123 
 
General Method C: Adapted from reference (260). To a mixture of the selected di-substituted 
benzophenone (1.0eq) and triphenylphosphine (1.2eq) under a N2 atmosphere, 5mL of anhydrous 
MeCN was added and the reaction mixture refluxed. A solution of methyl-2-hydroxyisobutyrate 
(1.2eq) and DIAD (1.2eq) in anhydrous MeCN was then added slowly over a period of 3-4 hours. 
The reaction mixture was then refluxed for a further 7-14 hours. The solvent was removed under 
vacuum, and the remaining residue was purified without further work up. 
General Method D: Adapted from reference (179). The methyl ester (1.0 eq) of the fenofibric acid 
derivative was dissolved in a mixture of THF and water (1:1). Sodium hydroxide (5.0 eq) was then 
added, and the reaction mixture stirred under a N2 atmosphere until the complete disappearance of 
the ester as monitored via TLC. The THF was then evaporated, and the remaining aqueous solution 
was diluted with water. The solution was then acidified to pH 1 using concentrated HCl, and the 
resulting precipitate extracted using chloroform. The combined organic layers were then dried over 
anhydrous Na2SO4, filtered, and the solvent removed under vacuum.  
General Method E: Adapted from reference (283). The fenofibric acid derivative (1.0eq) was 
dissolved in anhydrous DCM, and triethylamine (1.2eq), HBTU (1.2eq) and the selected amine 
(1.2eq) was then added, with the reaction mixture then stirred for between 4 hours to overnight. The 
reaction mixture was then diluted with DCM, washed with 1M HCl, water and brine. The organic 
layer was then dried over anhydrous Na2SO4, filtered, and the solvent removed under vacuum.  
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8.2.2 Compound characterization 
 (4-Chlorophenyl)(4-methoxyphenyl)methanone (35a) 
 
According to General Method A, 4-chlorobenzoyl chloride (1.41ml, 11.00mmol) was reacted with 
anisole (1.20ml, 11.04mmol) and AlCl3 (1.600g, 12.00mmol) in DCM (20mL) for 24 hours to 
afford 35a. 
Yield: 67% 
Appearance: White solid 
Purification: Recrystallized from EtOAc/hexane 
Melting Point: 123-124°C. Reported 123-125°C. 
m/z (ESI+) [MH]+: Calculated 247.0526, found 247.0518 
1H NMR (400 MHz, CDCl3)įGJ = 8.8 Hz, 2H), 7.71 (d, J = 8.4 Hz, 2H), 7.46 (d, J = 8.4 
Hz, 2H), 6.97 (d, J = 8.8 Hz, 2H), 3.90 (s, 3H) 
FTIR (KBr): cm-1 1639 (conj. ketone C=O); 1605, 1482 (aromatic C-C); 1255 (ether C-O); 760 
(C-Cl) 
 
(4-Methoxyphenyl)(4-(trifluoromethyl)phenyl)methanone (35b) 
 
According to General Method A, 4-trifluoromethylbenzoyl chloride (0.50ml, 3.37mmol) was 
reacted with anisole (0.40ml, 3.7mmol) and AlCl3 (0.495g, 3.7mmol) in DCM (20ml) for 24 hours 
to afford 35b. 
Yield: 83% 
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Appearance: White solid 
Purification: Recrystallized from EtOAc/hexane 
Melting Point: 118-119°C 
m/z (ESI+) [MH]+: Calculated 281.0789, found 281.0794 
1H NMR (400 MHz, CDCl3)į± 7.80 (m, 4H), 7.75 (d, J = 8.1 Hz, 2H), 6.99 (d, J = 8.9 Hz, 
2H), 3.91 (s, 3H) 
FTIR (KBr): cm-1 1677 (conj. ketone C=O); 1601, 1411 (aromatic C-C); 1328 (ether C-O); 1138 
(C-F) 
 
(4-Chlorophenyl)(4-hydroxyphenyl)methanone (36a) 
 
According to General Method B, 35a (0.600g, 2.43mmol) and pyridine.HCl (1.427g, 12.40mmol)  
were irradiated in a standard microwave oven at 240W for 16 minutes to afford 36a. 
Yield: 71% 
Appearance: White solid 
Purification: Radial thin-layer chromatography. EtOAc/ hexane (1:19) to pure EtOAc 
Melting Point: 178-180°C. Reported 177-182°C. 
m/z (ESI+) [MH]+: Calculated 233.0369, found 233.0371  
1H NMR (400 MHz, CDCl3)į± 7.69 (m, 4H), 7.45 (d, J = 8.3 Hz, 2H), 6.89 (d, J = 8.6 Hz, 
2H) 
FT-IR (KBr):  cm-1 3337 (phenolic OH); 1645 (conj. ketone C=O); 1598, 1570 (aromatic C-C); 
1313 (phenolic C-O); 836 (C-Cl) 
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(4-Hydroxyphenyl)(4-(trifluoromethyl)phenyl)methanone (36b) 
 
 
According to General Method B, 35b (0.824g, 2.84mmol) and pyridine.HCl (1.427g, 14.72mmol)  
were irradiated with in a microwave reactor at variable power and 200°C for 16 minutes to afford 
36b. 
Yield: 67% 
Appearance: White solid 
Purification: Radial thin-layer chromatography, EtOAc/ hexane (1:19) to pure EtOAc 
Melting Point: 145-146°C 
m/z (ESI+) [MH]+: Calculated 267.0633, found 267.0633  
1H NMR (400 MHz, CDCl3)įGJ = 8.3Hz, 2H), 7.80-7.74 (m, 4H), 6.93 (d, J = 8.8 Hz, 
2H) 
FT-IR (KBr):  cm-1 3326 (phenolic OH); 1643 (conj. ketone C=O); 1601 (aromatic C-C); 1315 
(phenolic C-O); 1149 (C-F) 
 
Methyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate (37a) 
 
According to General Method C, 36a (0.463g, 1.99 mmol) was reacted with methyl-2-
hydroxyisobutyrate (0.280ml, 2.40mmol), PPh3 (0.632g, 2.41mmol) and DIAD (0.470ml, 
2.40mmol) in MeCN (5ml) for 15 hours to afford 37a. 
Yield: 52% 
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Appearance: Light yellow solid 
Purification: Radial thin-layer chromatography, EtOAc/hexane (1:99) to pure EtOAc 
Melting Point: 75-79°C 
m/z (ESI+) [MH]+: Calculated 333.0888, found 333.0883  
1H NMR (400 MHz, CDCl3): įGJ = 8.5 Hz, 2H), 7.71 (d, J = 8.3 Hz, 2H), 7.45 (d, J = 8.3 
Hz, 2H), 6.85 (d, J = 8.5 Hz, 2H), 3.78 (s, 3H), 1.68 (s, 6H)  
FT-IR (KBr):  cm-1 1750 (ester C=O); 1652 (conj. ketone C=O); 1600 (aromatic C-C); 1148 (C-
O); 763 (C-Cl) 
 
Methyl 2-methyl-2-(4-(4-(trifluoromethyl)benzoyl)phenoxy)propanoate (37b) 
 
According to General Method C, 36b (0.492g, 1.85 mmol) was reacted with methyl-2-
hydroxyisobutyrate (0.28ml, 2.43mmol), PPh3 (0.634g, 2.42mmol) and DIAD (0.48ml, 2.42mmol) 
in MeCN (5ml) for 15 hours 45 minutes to afford 37b. 
Yield: 69% 
Appearance: Light yellow solid 
Purification: Radial thin-layer chromatography, EtOAc/hexane (1:99) to pure EtOAc 
Melting Point: 80-82°C 
m/z (ESI+) [MH]+: Calculated 367.1157, found 367.1154 
1H NMR (400 MHz, CDCl3): įGJ = 8.0 Hz, 2H), 7.79 ± 7.72 (m, 4H), 6.86 (d, J = 9.0 Hz, 
2H), 3.78 (s, 3H), 1.68 (s, 6H) 
FT-IR (KBr):  cm-1 1741 (ester C=O); 1661 (conj. ketone C=O); 1598 (aromatic C-C); 1318 (C-
O); 1173, 1144 (C-F) 
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Methyl 2-(4-(4-hydroxybenzoyl)phenoxy)-2-methylpropanoate (37c) 
 
AccoUGLQJ WR *HQHUDO 0HWKRG & ¶-dihydroxybenzophenone (0.501g, 2.33 mmol) was reacted 
with methyl-2-hydroxyisobutyrate (0.32ml, 2.80mmol), PPh3 (0.733g, 2.79mmol) and DIAD 
(0.55ml, 2.79mmol) in MeCN (5ml) for 15 hours to afford 37c. 
Yield: 32% 
Appearance: Light yellow solid 
Purification: Column chromatography. EtOAc/hexane (3:7) 
Melting Point: 108-115°C 
m/z (ESI+) [MH]+: Calculated 315.1232, found 315.1223 
1H NMR (400 MHz, CDCl3): į± 7.69 (m, 4H), 6.91 (d, J = 8.7 Hz, 2H), 6.85 (d, J = 7.9 Hz, 
2H), 3.78 (s, 3H), 1.67 (s, 6H) 
FT-IR (KBr):  cm-1 3250 (phenolic OH); 1735 (ester C=O); 1621 (conj. ketone C=O); 1602, 1586 
(aromatic C-C); 1286, 1252 (C-O)  
 
Fenofibric acid/ 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoic acid (22) 
 
According to General Method D, 37a (0.310g, 0.93mmol) was reacted with NaOH (0.224g, 
5.60mmol) in THF/water 1:1 (10ml) for 8 hours to afford 22.  
Yield: 92% 
Appearance: White solid 
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Purification: No purification needed 
Melting Point: 174-175°C. Reported 177-179°C. 
m/z (ESI+) [MH]+: Calculated 319.0737, found 319.0722 
1H NMR (400 MHz, CDCl3): įGJ = 8.9 Hz, 2H), 7.71 (d, J = 8.6 Hz, 2H), 7.45 (d, J = 8.6 
Hz, 2H), 6.95 (d, J = 8.9 Hz, 2H), 1.70 (s, 6H) 
FT-IR (KBr):  cm-1 2952 (carboxylic acid OH); 1744 (carboxylic acid C=O); 1633 (conj. ketone 
C=O); 1599 (aromatic C-C); 1263 (C-O); 1150, 769 (C-Cl) 
 
2-Methyl-2-(4-(4-(trifluoromethyl)benzoyl)phenoxy)propanoic acid (38a) 
 
According to General Method D, 37b (0.336g, 0.92mmol) was reacted with NaOH (0.198g, 
4.95mmol) in THF/water 1:1 (10ml) for 6 hours to afford 38a. 
Yield: 96% 
Appearance: White solid 
Purification: No purification needed 
Melting Point: 139-141°C 
m/z (ESI+) [MH]+: Calculated 353.1000, found 353.0979 
1H NMR (400 MHz, CDCl3): įGJ = 8.1 Hz, 2H), 7.79 ± 7.72 (m, 4H), 6.95 (d, J = 7.3 Hz, 
2H), 1.69 (s, 6H) 
FT-IR (KBr):  cm-1 3046 (carboxylic acid OH); 1747 (carboxylic acid C=O); 1637 (conj. ketone 
C=O); 1599 (aromatic C-C); 1324 (C-O), 1155, 1129 (C-F) 
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2-(4-(4-Hydroxybenzoyl)phenoxy)-2-methylpropanoic acid (38b) 
 
According to General Method D, 37c (0.216g, 0.69mmol) was reacted with NaOH (0.192g, 
4.80mmol) in THF/water 1:1 (8ml) for 24 hours to afford 38b.  
 Yield: 91% 
Appearance: White solid 
Purification: Acid-base extraction 
Melting Point: 176-180°C 
m/z (ESI+) [MH]+: Calculated 301.1076, found 301.1076 
1H NMR (400 MHz, CDCl3): įGJ = 8.9 Hz, 4H), 6.93 (d, J = 8.9 Hz, 2H), 6.88 (d, J = 8.8 
Hz, 2H), 1.68 (s, 6H)  
FT-IR (KBr): cm-1 3324 (carboxylic acid OH); 1702 (carboxylic acid C=O); 1604 (conj. ketone 
C=O); 1583 (aromatic C-C); 1329, 1288 (C-O)  
 
N-(exo-Norborn-2-yl)-2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanamide (30a) 
 
According to General Method E, fenofibric acid (0.075g, 0.24mmol) was reacted with exo-2-
aminonorbornane (0.031ml, 0.26mmol), HBTU (0.098g, 0.26mmol), and Et3N (0.036ml, 
0.26mmol) in DCM (5ml) for 4 hours to afford 30a. 
Yield: 88% 
Appearance: White solid 
Purification: Radial thin-layer chromatography. EtOAc/hexane (1:9) to EtOAc/hexane (1:1) 
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Melting Point: 140-141°C 
m/z (ESI+) [MH]+: Calculated 412.1679, found 412.1682 
1H NMR (400 MHz, CDCl3): įGGJ = 13.9, 8.8 Hz, 4H), 7.47 (d, J = 8.7 Hz, 2H), 6.96 (d, J 
= 8.7 Hz, 2H), 6.23 (d, J = 6.7 Hz, 1H), 3.74 (td, J = 7.4, 3.6 Hz, 1H), 2.21 (d, J = 20.1 Hz, 2H), 
1.79 (dd, J = 13.6, 8.6 Hz, 1H), 1.59 (d, J = 2.4 Hz, 6H), 1.56 ± 1.40 (m, 2H), 1.30 ± 1.22 (m, 1H), 
1.17 ± 1.07 (m, 4H) 
13C NMR (100 MHz, CDCl3): į
128.70, 119.37, 81.92, 52.81, 42.20, 40.18, 35.71, 35.57, 28.16, 26.45, 25.60, 25.06 
FT-IR (KBr):  cm-1 3352 (amide NH); 1660 (amide C=O); 1637 (conj. ketone C=O); 1601 
(aromatic C-C) 1248 (C-O); 1147, 763 (C-Cl) 
 
N-(R-(+)-Born-2-yl)-2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanamide (30b) 
 
 
According to General Method E, fenofibric acid (0.070g, 0.22mmol) was reacted with R(+)-
bornylamine (0.044g, 0.29mmol), HBTU (0.102g, 0.27mmol), and Et3N (0.037ml, 0.26mmol) for 
22 hours 45 minutes in DCM (5ml) to afford 30b. 
Yield: 91% 
Appearance: White solid 
Purification: Radial thin-layer chromatography. EtOAc/hexane (1:9) to EtOAc/hexane (1:1) 
Melting Point: 119-121°C 
m/z (ESI+) [MH]+: Calculated 454.2149, found 454.2113 
1H NMR (400 MHz, CDCl3): įGJ = 8.7 Hz, 2H), 7.72 (d, J = 8.5 Hz, 2H), 7.46 (d, J = 8.5 
Hz, 2H), 6.99 (d, J = 8.7 Hz, 2H), 6.43 (d, J = 8.8 Hz, 1H), 4.28 ± 4.20 (m, 1H), 2.39 ± 2.28 (m, 
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1H), 1.76 ± 1.66 (m, 1H), 1.66 ± 1.64 (m, 1H), 1.62 (d, J = 7.0 Hz, 6H), 1.37 ± 1.17 (m, 2H), 1.09 ± 
1.02 (m, 1H), 0.95 (s, 3H), 0.85 (s, 3H), 0.78 (s, 3H), 0.70 (dd, J = 13.2, 4.5 Hz, 1H) 
13C NMR (100 MHz, CDCl3): į
128.69, 119.27, 82.12, 53.83, 49.57, 48.27, 44.89, 37.55, 28.36, 27.93, 25.64, 25.36, 19.82, 18.69, 
13.85 
FT-IR (KBr):  cm-1 3357 (amide NH); 1666 (amide C=O); 1651 (conj. ketone C=O); 1604 
(aromatic C-C); 1247 (C-O); 1150, 764 (C-Cl) 
 
N-(Adamantan-1-yl)-2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanamide (30c) 
 
According to General Method E, fenofibric acid (0.060g, 0.19mmol) was reacted with 1-
adamantylamine (0.034g, 0.23mmol), HBTU (0.085g, 0.23mmol), and Et3N (0.032ml, 0.23mmol) 
for 24 hours in DCM (5ml) to afford 30c. 
Yield: 92% 
Appearance: White crystals 
Purification: Recrystallized from EtOAc/CHCl3 
Melting Point: 167-169°C 
m/z (ESI+) [MH]+: Calculated 452.1992, found 452.1977 
1H NMR (400 MHz, CDCl3): įGJ = 8.6 Hz, 2H), 7.73 (d, J = 8.3 Hz, 2H), 7.46 (d, J = 8.3 
Hz, 2H), 6.97 (d, J = 8.6 Hz, 2H), 6.08 (s, 1H), 2.07 (br s, 3H), 1.96 (br s, 6H), 1.66 (br s, 6H), 1.57 
(br s, 6H) 
13C NMR (100 MHz, CDCl3): į
119.13, 82.00, 51.84, 41.38, 36.33, 29.43, 25.27 
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FT-IR (KBr):  cm-1 3346 (amide NH); 1665 (amide C=O); 1652 (conj. ketone C=O); 1604 
(aromatic C-C); 1246 (C-O); 1151, 765 (C-Cl) 
 
N-(Piperidin-1-yl)-2-(4-(4-(trifluoromethyl)benzoyl)phenoxy)-2-methylpropanamide (31a) 
 
According to General Method E, 38a (0.058g, 0.16mmol) was reacted with 1-aminopiperidine 
(0.028ml, 0.20mmol), HBTU (0.078g, 0.21mmol), and Et3N (0.028ml, 0.20mmol) for 24 hours in 
DCM (5ml) to afford 31a. 
Yield: 91% 
Appearance: White solid 
Purification: Radial thin-layer chromatography. EtOAc/hexane (1:9) to pure EtOAc 
Melting Point: 154-156°C 
m/z (ESI+) [MH]+: Calculated 435.1895, found 435.1895 
1H NMR (400 MHz, CDCl3): įGJ = 8.1 Hz, 2H), 7.78 (d, J = 8.9 Hz, 2H), 7.76 (d, J = 8.1 
Hz, 2H), 7.10 (br s, 1H), 7.00 (d, J = 8.9 Hz, 2H), 2.71 ± 2.68 (m, 4H), 1.70 (p, J = 5.6 Hz, 4H), 
1.63 (s, 6H), 1.44 ± 1.34 (m, 2H) 
13C NMR (100 MHz, CDCl3): į
56.84, 25.41, 25.31, 23.24 
FT-IR (KBr):  cm-1 3307 (amide NH); 1677 (amide C=O); 1648 (conj. ketone C=O); 1600 
(aromatic C-C); 1313 (C-O); 1171, 1146 (CF3) 
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N-(exo-norborn-2-yl)-2-methyl-2-(4-(4-(trifluoromethyl)benzoyl)phenoxy)propanamide (31b) 
 
According to General Method E, 38a (0.061g, 0.17mmol) was reacted with exo-2-aminonorbornane 
(0.024ml, 0.20mmol), HBTU (0.078g, 0.21mmol), and Et3N (0.028ml, 0.20mmol) for 24 hours in 
DCM (5ml) to afford 31b. 
Yield: 88% 
Appearance: White solid 
Purification: Radial thin-layer chromatography. EtOAc/hexane (1:9) to EtOAc/hexane (1:1) 
Melting Point: 103-106°C 
m/z (ESI+) [MH]+: Calculated 446.1943, found 446.1939 
1H NMR (400 MHz, CDCl3): įGJ = 8.1 Hz, 2H), 7.78 (d, J = 8.9 Hz, 2H), 7.76 (d, J = 8.1 
Hz, 2H), 6.97 (d, J = 8.9 Hz, 2H), 6.21 (d, J = 7.6 Hz, 1H), 3.74 (td, J = 7.6, 3.5 Hz, 1H), 2.25 ± 
2.16 (m, 2H), 1.79 (ddd, J = 13.1, 8.0, 1.9 Hz, 1H), 1.60 (d, J = 2.4 Hz, 6H), 1.56 ± 1.39 (m, 2H), 
1.30 ± 1.21 (m, 1H), 1.17 ± 1.06 (m, 4H) 
13C NMR (100 MHz, CDCl3): į
52.83, 42.19, 40.18, 35.71, 35.57, 28.16, 26.44, 25.61, 25.06 
FT-IR (KBr):  cm-1 3366 (amide NH); 1659 (amide C=O); 1643 (conj. ketone C=O); 1602 
(aromatic C-C); 1248 (C-O); 1181, 1148 (CF3) 
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N-(R-(+)-Born-2-yl)-2-(4-(4-(trifluoromethyl)benzoyl)phenoxy)-2-methylpropanamide (31c) 
 
According to General Method E, 38a (0.050g, 0.14mmol) was reacted with R(+)-bornylamine 
(0.026g, 0.17mmol), HBTU (0.065g, 0.17mmol), and Et3N (0.024ml, 0.17mmol) for 23 hours in 
DCM (5ml) to afford 31c. 
Yield: 93% 
Appearance: White solid 
Purification: Radial thin-layer chromatography. EtOAc/hexane (1:9) to EtOAc/hexane (1:1) 
Melting Point: 81-82°C 
m/z (ESI+) [MH]+: Calculated 488.2412, found 488.2406 
1H NMR (400 MHz, CDCl3): įGJ = 8.1 Hz, 2H), 7.79 (d, J = 8.9 Hz, 2H), 7.76 (d, J = 8.1 
Hz, 2H), 7.01 (d, J = 8.9 Hz, 2H), 6.41 (d, J = 9.1 Hz, 1H), 4.30 ± 4.17 (m, 1H), 2.39 ± 2.28 (m, 
1H), 1.78 ± 1.67 (m, 2H), 1.63 (d, J = 7.2 Hz, 6H), 1.34 ± 1.17 (m, 2H), 1.10 ± 1.01 (m, 1H), 0.95 
(s, 3H), 0.85 (s, 3H), 0.78 (s, 3H), 0.70 (dd, J = 13.4, 4.5 Hz, 1H)  
13C NMR (100 MHz, CDCl3) į, 173.81, 159.10, 132.18, 129.96, 125.41, 119.27, 82.18, 
53.84, 49.57, 48.28, 44.88, 37.56, 28.37, 27.92, 25.65, 25.36, 19.81, 18.69, 13.85 
FT-IR (KBr):  cm-1 3370 (amide NH); 1667 (amide C=O); 1656 (conj. ketone C=O); 1604 
(aromatic C-C); 1246 (C-O); 1167, 1150 (CF3) 
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N-(Adamantan-1-yl)-2-methyl-2-(4-(4-(trifluoromethyl)benzoyl)phenoxy)propanamide (31d) 
 
According to General Method E, 38a (0.050g, 0.14mmol) was reacted with 1-admantylamine 
(0.026g, 0.17mmol), HBTU (0.065g, 0.17mmol), and Et3N (0.024ml, 0.17mmol) for 24 hours in 
DCM (5ml) to afford 31d. 
Yield: 88% 
Appearance: White solid 
Purification: Radial thin-layer chromatography. DCM/hexane (1:1) to pure DCM 
Melting Point: 151-152°C 
m/z (ESI+) [MH]+: Calculated 486.2256, found 486.2248 
1H NMR (396 MHz, CDCl3): į 7.86 (d, J = 8.1 Hz, 2H), 7.79 (d, J = 8.9 Hz, 2H), 7.75 (d, J = 8.1 
Hz, 2H), 6.98 (d, J = 8.9 Hz, 2H), 6.06 (s, 1H), 2.07 (br s, 3H), 1.99 ± 1.94 (m, 6H), 1.70 ± 1.64 (m, 
6H), 1.58 (br s, 6H) 
13C NMR (100 MHz, CDCl3): į
119.14, 82.07, 51.86, 41.38, 36.32, 29.43, 25.27 
FT-IR (KBr):  cm-1 3422 (amide NH); 1687 (amide C=O); 1660 (conj. ketone C=O); 1597 
(aromatic C-C); 1276 (C-O); 1175, 1143 (CF3) 
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N-(Piperidin-1-yl)-2-(4-(4-hydroxybenzoyl)phenoxy)-2-methylpropanamide (32a) 
 
According to General Method E, 38b (0.070g, 0.23mmol) was reacted with 1-aminopiperidine 
(0.030ml, 0.28mmol), HBTU (0.106g, 0.28mmol), and Et3N (0.039ml, 0.28mmol) for 23 hours 30 
minutes in DCM (5ml) to afford 32a. 
Yield: 29% 
Appearance: White solid 
Purification: Radial thin-layer chromatography. CHCl3. Product then precipitated out of CHCl3 
upon addition of hexane. 
Melting Point: 217-218°C 
m/z (ESI+) [MH]+: Calculated 383.1971, found 383.1968 
1H NMR (400 MHz, CDCl3): į± 7.69 (m, 4H), 7.02 ± 6.92 (m, 4H), 2.74 ± 2.63 (m, 4H), 
1.71 ± 1.63 (m, 4H), 1.62 (s, 6H), 1.42 ± 1.33 (m, 2H) 
13C NMR (100 MHz, CDCl3): į
115.15, 81.33, 56.61, 25.15, 23.05 
FT-IR (KBr):  cm-1 3437 (phenolic OH); 3236 (amide NH); 1659 (amide C=O); 1645 (conj. ketone 
C=O); 1588 (aromatic C-C); 1238, 1151 (C-O)  
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N-(exo-Norborn-2-yl)-2-(4-(4-hydroxybenzoyl)phenoxy)-2-methyl propanamide (32b) 
 
According to General Method E, 38b (0.050g, 0.17mmol) was reacted with exo-2-aminonorbornane 
(0.024ml, 0.20mmol), HBTU (0.076g, 0.20mmol), and Et3N (0.028ml, 0.20mmol) for 24 hours in 
DCM (5ml) to afford 32b. 
Yield: 30% 
Appearance: White solid 
Purification: Radial thin-layer chromatography. EtOAc/hexane (1:9) to EtOAc/hexane (1:1) 
Melting Point: 117-119°C 
m/z (ESI+) [MH]+: Calculated 394.2018, found 394.2022 
1H NMR (400 MHz, CDCl3): įGJ = 8.8 Hz, 4H), 6.98 ± 6.94 (m, 4H), 6.41 (d, J = 7.5 Hz, 
1H), 3.75 (td, J = 7.7, 3.5 Hz, 1H), 2.27 ± 2.18 (m, 2H), 1.87 ± 1.75 (m, 1H), 1.59 (d, J = 2.6 Hz, 
6H), 1.55 ± 1.39 (m, 2H), 1.28 ± 1.22 (m, 2H), 1.18 ± 1.09 (m, 4H) 
13C NMR (100 MHz, CDCl3): į
52.98, 42.24, 40.16, 38.78, 35.72, 35.61, 28.15, 26.42, 25.58, 25.07 
FT-IR (KBr):  cm-1 3281 (phenolic OH); 3281 (amide NH); 1652 (amide C=O); 1638 (conj. ketone 
C=O); 1605 (aromatic C-C); 1250, 1150 (C-O)  
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N-(R-(+)-Born-2-yl)-2-(4-(4-hydroxybenzoyl)phenoxy)-2-methylpropanamide (32c) 
 
According to General Method E, 38b (0.040g, 0.13mmol) was reacted with R(+)-bornylamine 
(0.025mg, 0.16mmol), HBTU (0.061g, 0.16mmol), and Et3N (0.023ml, 0.16mmol) for 24 hours in 
DCM (5ml) to afford 32c. 
Yield: 40% 
Appearance: White solid 
Purification: Radial thin-layer chromatography. EtOAc/hexane (1:9) to EtOAc/hexane (1:1) 
Melting Point: 82-85°C 
m/z (ESI+) [MH]+: Calculated 436.2488, found 436.2482 
1H NMR (400 MHz, CDCl3): į± 7.70 (m, 4H), 6.99 (d, J = 8.8 Hz, 2H), 6.90 (d, J = 8.7 Hz, 
2H), 6.61 (d, J = 9.2 Hz, 1H), 4.27 ± 4.20 (m, 1H), 2.39 ± 2.30 (m, 1H), 1.96 (br s, 1H), 1.76 ± 1.69 
(m, 1H), 1.67 ± 1.65 (m, 1H), 1.61 (d, J = 6.6 Hz, 6H), 1.34 ± 1.22 (m, 2H), 1.08 (ddd, J = 13.4, 
8.6, 5.4 Hz, 1H), 0.95 (s, 3H), 0.85 (s, 3H), 0.79 (s, 3H), 0.74 (dd, J = 13.4, 4.5 Hz, 1H) 
13C NMR (100 MHz, CDCl3): į.91, 132.77, 131.81, 119.45, 115.33, 82.01, 
53.98, 49.59, 48.28, 37.48, 28.35, 27.93, 25.65, 25.34, 19.80, 18.65, 13.84 
FT-IR (KBr):  cm-1 3227 (phenolic OH); 3227 (amide NH); 1652 (amide C=O); 1602 (conj. ketone 
C=O); 1282, 1151 (C-O)  
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N-(Adamantan-1-yl)-2-(4-(4-hydroxybenzoyl)phenoxy)-2-methylpropanamide (32d) 
 
According to General Method E, 38b (0.070g, 0.23mmol) was reacted with 1-adamantylamine 
(0.042mg, 0.28mmol), HBTU (0.132g, 0.28mmol), and Et3N (0.049ml, 0.28mmol) for 48 hours in 
DCM (5ml) to afford 32d. 
Yield: 39% 
Appearance: White crystals 
Purification: Radial thin-layer chromatography. EtOAc/hexane (3:7). Product was then 
recrystallized from CHCl3/hexane 
Melting Point: 172-173°C 
m/z (ESI+) [MH]+: Calculated 434.2330, found 434.2331 
1H NMR (400 MHz, CDCl3): į± 7.73 (m, 4H), 7.03 (s, 1H), 6.99 ± 6.94 (m, 4H), 6.22 (s, 
1H), 2.07 (br s, 3H), 1.99 (br s, 6H), 1.67 (br s, 6H), 1.58 (br s, 6H) 
13C NMR (100 MHz, CDCl3): į
119.34, 115.36, 81.89, 52.05, 41.34, 36.30, 29.42, 25.28 
FT-IR (KBr):  cm-1 3207 (phenolic OH); 3207 (amide NH); 1637 (amide C=O); 1608 (conj. ketone 
C=O); 1283, 1150 (C-O)  
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2-Methyl-3-phenylmaleic anhydride (40) 
 
To anhydrous 1,2 dichloroethane (25ml) under a N2 atmosphere, ethyl benzoylformate (1.00ml, 
6.30mmol), propionic anhydride (1.62ml, 12.60mmol), TiCl4 (2.76ml of a 1:1 solution of 
TiCl4/DCM, 12.60mmol), and n-Bu3N (1.80ml, 7.56mmol) were added. The reaction mixture was 
then refluxed for 12 hours. It was then cooled to 0°C and a saturated solution of aqueous NH4Cl 
(10ml) was added, and the resulting mixture was stirred for 30 minutes. 10ml of water was added, 
and the organic layer was then separated. The aqueous layer was then extracted with DCM (2 x 
15ml) before being discarded, and the combined organic extract was washed with 2M HCl (20ml), 
water (20ml), and brine (20ml) before being dried over anhydrous Na2SO4, and the solvent removed 
under vacuum. 
Yield: 28% 
Appearance: White solid 
Purification: Column chromatography. EtOAc/hexane (1:19) to EtOAc/hexane (3:7).  
Melting Point: 90-92°C. Reported 98-100°C. 
m/z (ESI+) [MH]+: Calculated 189.0551, found 189.0546 
1H NMR (400 MHz, CDCl3): įGGJ = 6.8, 3.0 Hz, 2H), 7.56 ± 7.50 (m, 3H), 2.33 (s, 3H) 
FT-IR (KBr):  cm-1 1764 (anhydride C=O); 1268 (anhydride C-O); 922 (alkene =C-H) 
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N-exo-Norborn-2-yl-2-methyl-3phenylmaleimide (41) 
 
 
To a solution of 40 (0.030g, 0.16mmol) in anhydrous toluene (3ml) under a N2 atmosphere, a 
solution of exo-2-aminonorbornane (0.018g, 0.16mmol) in anhydrous toluene was added dropwise. 
The reaction mixture was stirred for 1 hour. Anhydrous ZnI2 (0.051g, 0.16mmol) was then added 
and the reaction mixture was heated to reflux. A solution of HMDS in anhydrous toluene (0.039g, 
0.24mmol) was then added in three portions over 30 minutes. The reaction mixture was then 
refluxed for a further 2 hours. The reaction mixture was then cooled and poured into 0.5M HCl. 
The aqueous layer was extracted with EtOAc, and the combined organic layers was washed with 
saturated aq. NaHCO3 and brine, dried over anhydrous Na2SO4 and the solvent removed under 
vacuum. 
Yield: 86% 
Appearance: Yellow oil 
Purification: Radial thin-layer chromatography. EtOAc/hexane (1:99) to EtOAc/hexane (1:9) 
m/z (ESI+) [MH]+: Calculated 282.1494, found 282.1496 
1H NMR (400 MHz, CDCl3): įGGJ = 8.2, 1.6 Hz, 2H), 7.51 ± 7.38 (m, 3H), 4.07 ± 3.96 (m, 
1H), 2.38 (d, J = 19.9 Hz, 2H), 2.23 ± 2.18 (m, 2H), 2.16 (s, 3H), 1.68 (ddd, J = 12.5, 8.9, 2.2 Hz, 
1H), 1.60 ± 1.49 (m, 2H), 1.32 (td, J = 8.6, 2.1 Hz, 1H), 1.26 ± 1.15 (m, 2H) 
FT-IR (KBr):  cm-1 2957 (alkyl C-H); 1698 (imide C=O); 1371 (imide C-N); 694 (alkene =C-H) 
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8.3 Pharmacology 
8.3.1 Cell culture method 
Chinese Hamster Ovary (CHO) cells stably expressing the human CB2 receptor were provided by 
Pfizer Neusentis Ltd. All cell culture procedures were performed under sterile conditions in a class 
II laminar flow cabinet. All culture reagents were warmed to 37°C prior to use. Cells were cultured 
in 175cm2 FXOWXUH IODVNV FRQWDLQLQJ 'XOEHFFR¶V 0RGLILHG (DJOH 0HGLXP 1XWULHQW 0L[WXUH )
(DMEM/F12) supplemented with 10% fetal bovine serum, 2mM L-glutamine and 400 µg/ml G 
418. Cells were cultured for 2-3 days in a humidified incubator (37°C, 5 % CO2) until ~90% 
confluent, and then passaged. Cells were washed once with phosphate-buffered saline (PBS), and 
then incubated with a trypsin/EDTA solution for approximately 3 minutes to allow detachment of 
the cells from the culture flask. The cell suspension was diluted in culture medium to deactivate the 
trypsin, and then cells were collected by centrifugation at 200g for 3 minutes. The cell pellet was 
suspended in fresh culture medium, and the number of cells determined using a Bio-Rad T&
Automated Cell Counter. Cells were subsequently reseeded into new culture flasks containing fresh 
culture medium. 
8.3.2 Preparation of membrane homogenates 
The procedure was adapted from method previously described in (284). Once the cells were 
confluent, trypsin was added to the culture flasks for no more than1 minute to allow for cell 
detachment but to minimize proteolytic degradation of the surface proteins. Cells were then 
collected by centrifugation at 200g for 3 min. All subsequent steps were performed at 0 -4°C. Cell 
pellets were resuspended in cold homogenization buffer (50 mM Tris, 5mM MgCl2, 2mM EDTA, 
pH 7.4), combined, and homogenized using a Polytron homogenizer. The suspension was then 
centrifuged (30,000g for 10 minutes at 4°C), and the supernatant discarded. The pellet was then 
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resuspended in fresh homogenization buffer and the process was repeated twice. The final 
membrane pellet was then resuspended in homogenization buffer and the protein concentration was 
determined by Lowry protein assay (285). The membrane concentration was then adjusted to 2.5 
mg/ml protein and was stored in aliquots at -80°C. 
8.3.3 [3H]CP55940 competition binding assay procedure 
The assay was adapted from the method previously described in (179). To assay tubes containing 
ȝORIDVVD\EXIIHU P07ULVP0('7$P00J&O2, 0.2mg/ml BSA, pH 7.0 at 30°C), 
ȝO RI >3H]CP55940 (~0.5nM) in drug buffer (50mM Tris, 2mM EDTA, 5mM MgCl2, 5mg/ml 
%6$S+ DW &ȝORIcompeting ligand FRQFHQWUDWLRQ UDQJHȝ0WRQ0  in drug 
EXIIHU DQG ȝO of CB2 receptor-expressing CHO cells membrane homogenate (1mg/ml) was 
added, giving a final assay volume of 1ml. Basal binding levels were determined using drug buffer 
without any competing ligand. Non-specific binding (NSB) ZDVGHWHUPLQHGLQWKHSUHVHQFHRIȝ0
of unlabeled CP55940. All data points were carried out in duplicate. The assay tubes were vortexed 
for 1-2 seconds, and were then incubated in a water bath at 30°C for 90 minutes.  
 Following incubation, the membranes were harvested using a cell filter harvester (M-24 
Cell Harvester, Brandel) and glass fiber filters (GF/B filters, Brandel) pre-soaked with drug buffer, 
and were washed with cold buffer (50mM Tris, 2mM EDTA, 5mM MgCl2, 0.5mg/ml BSA, pH 7.0 
at 4°C) three times to separate bound and unbound ligand. The filters were then collected in 
scintillation vials and 3ml of scintillation IOXLG 8OWLPD*ROG;53HUNLQ(OPHUZDV DGGHG WR
each vial. The bound radioligand was then quantified using a liquid scintillation counter (Tri-Carb 
2100TR Liquid Scintillation Analyzer, Packard). 
 Specific binding was calculated by subtracting NSB from total binding. Non-linear 
regression analysis was then performed using GraphPad Prism 5, and the Ki value of each ligand 
was determined using the Cheng-Prusoff equation. The exact concentration of [3H]CP55940 was 
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calculated in each experiment using the mean total activity RIYLDOVFRQWDLQLQJȝORIXQILOWHUHG
[3H] CP55940, while the Kd of [3H]CP55940 was previously determined to be 0.5nM. 
8.3.4 [35S]*73Ȗ6ELQGLQJDVVD\SURFHGXUH 
The assay was adapted from the method previously described in reference (22). A mixture of CB2 
receptor-expressing CHO cells membrane homogenate (50ȝJPO DQG *'3 P0 LQ DVVD\
buffer (50mM Tris, 100mM NaCl, 10mM MgCl2, 0.2mg/ml BSA, pH 7.4 at 30°C) was incubated in 
water bath at 30°C for 20 minutes. Following incubation, 0.5ml of this mixture was added to assay 
WXEHVFRQWDLQLQJȝORI>35S]*73Ȗ644Q0DQGȝORIOLJDQG FRQFHQWUDWLRQUDQJHȝ0WR
0.1nM) in drug buffer (50mM Tris, 100mM NaCl, 10mM MgCl2, 5mg/ml BSA, pH 7.4 at 30°C), 
giving a final assay volume of 1ml. Basal levels were determined using drug buffer without any 
ligand. Non-specific binding was determined in the presence of ȝ0 XQODEHOHG *73Ȗ6. The 
maximal agonist-enhanced response was determLQHG LQ WKH SUHVHQFH RI ȝ0 &3 All data 
points were carried out in duplicate. The assay tubes were vortexed for 1-2 seconds, and were then 
incubated in a water bath at 30°C for 90 minutes.  
 Following incubation, the membranes were harvested using a cell filter harvester and glass 
fiber filters (GF/C filters, Brandel), and were washed with cold distilled water three times. The 
filters were then collected in scintillation vials and 3ml of scintillation fluid was added to each vial. 
The bound [35S] *73Ȗ6ZDVWKHQTXDQWLILHGXVLQJDOLTXLGVFLQWLOODWLRQFRXQWHU 
 Specific binding was calculated by subtracting NSB from total binding. Non-linear 
regression analysis was then performed using GraphPad Prism 5 in order to determine the Emax and 
the EC50. Results were expressed as a % of the maximal response. 
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APPENDIX 1 
EQUILIBRATION OF THE CANNABINOID RECEPTORS IN A POPC BILAYER 
Cannabinoid receptor CB1
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Cannabinoid receptor CB2 
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Cannabinoid receptor CB1 with SR141716 bound 
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Cannabinoid receptor CB1 with SR141716 bound (continued) 
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APPENDIX II 
PARTIAL CHARGES USED IN SR141716 TOPOLOGY 
FORCEFIELD: GROMOS 53a6 
 
 
SR141716 
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APPENDIX III 
LIGANDS USED IN DOCKING EVALUATION 
Cannabinoid receptor CB1 agonists 
Ligand Experimental pKi Reference 
2AG 6.3 (69) 
A796260 6.1 (220) 
AM1714 6.4 (215) 
AM411 8.2 (213) 
Anandamide 6.6 (236) 
BAY387271 8.7 (214) 
Cannabinol 6.5 (207) 
CP55940 9.2 (204) 
HU210 10.2 (202) 
JWH015 6.4 (211) 
JWH133 6.2 (219) 
O2545 8.9 (217) 
THC 7.3 (202) 
WIN55212-2 8.7 (207) 
 
Cannabinoid receptor CB1 antagonists 
Ligand Experimental pKi Reference 
AM281 7.9 (225) 
AM630 5.3 (216) 
CP272871 8.5 (226) 
DML23 7.0 (237) 
JTE907 5.6 (208) 
LY320135 6.9 (80) 
MK0364 9.5 (231) 
NESS0327 12.5 (228) 
NIDA41020 8.4 (227) 
NIDA41109 8.9 (227) 
O1270 7.3 (238) 
O2050 8.6 (64) 
SLV319 8.1 (230) 
SR141716 9.1 (221) 
SR147778 8.5 (223) 
  
176 
 
Cannabinoid receptor CB2 agonists 
Ligand Experimental pKi Reference 
AM 1241 8.5 (235) 
AM 1714 9.1 (215) 
Anandamide 6.1 (210) 
BAY 387271 8.2 (214) 
CP 55940 9.8 (204) 
HU 308 7.6 (234) 
JWH 015 7.9 (211) 
JWH 133 8.5 (218) 
JWH 267 8.1 (219) 
L 759633 8.2 (216) 
L 759656 7.9 (216) 
O 2545 9.9 (217) 
O 1812 5.4 (206) 
THC 7.1 (208) 
WIN 55212-2 9.6 (207) 
 
Cannabinoid receptor CB2 antagonists 
Ligand Experimental pKi Reference 
AM 281 5.4 (225) 
CP 272871 6.9 (226) 
JTE 907 7.4 (208) 
LY 320135 4.8 (80) 
MK 0364 6.5 (231) 
NESS 0327 7.7 (228) 
O 1184 8.1 (239) 
O 2050 8.8 (64) 
Sch 336 9.4 (232) 
SR 141716 6.9 (221) 
SR 144528 9.2 (224) 
SR 147778 6.4 (223) 
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APPENDIX IV 
RESIDUES IMPLICATED IN LIGAND BINDING VIA 
MUTAGENESIS STUDIES 
Cannabinoid receptor CB1 
Residue Ligand with possible interaction Reference 
D2.50 WIN55212-2 (248) 
K2.38 Classical and non-classical cannabinoids (242) 
F3.25 Anandamide (167) 
L3.29 CP55940, HU210, THC (243) 
G3.31 WIN55212-2 (247) 
F3.36 SR141716, WIN55212-2 (167) 
F268 CP55940, HU210, methanandamide (246) 
P269 CP55940, HU210, methanandamide (246) 
H270 CP55940, HU210, methanandamide (246) 
I271 CP55940, HU210, methanandamide (246) 
Y5.39 Anandamide, CP55940, WIN55212-2 (166) 
W5.43 SR141716, WIN55212-2 (167) 
C6.47 Classical and non-classical cannabinoids (245) 
W6.48 SR141716, WIN55212-2 (167) 
M6.55 CP55940, HU210, THC (243) 
S7.39 AM4056, CP55940, HU210, MK0364 (169,244) 
C7.42 SR141716 (184) 
 
Cannabinoid receptor CB2
 
Residue Ligand with possible interaction Reference 
K3.28 JWH015 (164) 
S3.31 Classical and non-classical cannabinoids (164) 
W4.50 HU210, 2-AG, CP55940, WIN55212-2 (254) 
S4.53 SR144528 (170) 
S4.57 SR144528 (170) 
W4.64 HU210, 2-AG, CP55940, WIN55212-2 (254) 
C174 CP55940, WIN55212-2, Anandamide (170,255) 
C175 SR144528, WIN55212-2 (170) 
C179 CP55940, WIN55212-2, Anandamide (170,255) 
Y5.39 Anandamide (166) 
W5.43 CP55940, WIN55212-2, SR144528 (171) 
F5.46 WIN55212-2 (165) 
W6.48 CP55940 (253) 
 
* Residues C2.59, V6.51, L6.52, L6.54, M6.55, L6.59, and T6.62 have been experimentally 
shown to be accessible in the binding site crevice of the CB2 receptor (251,252). 
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APPENDIX V 
PREDICTED BINDING AFFINITIES OF FENOFIBRATE 
DERIVATIVES ADOPTING THE PREDICTED BINDING 
CONFORMATION 
 
No Experimental pKi Predicted pKi 
24f 6.66 8.11 
24g 7.82 7.81 
24h 7.80 7.78 
25a 6.23 7.98 
25b 6.37 8.17 
25c 6.62 8.07 
25f 5.88 8.42 
26a 5.94 7.65 
26c 5.87 8.00 
26d 5.81 8.24 
26e 6.12 8.35 
27c 6.51 7.60 
27f 6.84 7.28 
28c 7.54 7.84 
28i 7.85 7.92 
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APPENDIX VI 
PHARMACOLOGY OF NOVEL FENOFIBRATE DERIVATIVES 
DESIGNED BASED ON MODELLING DATA 
 
 
 
 (A) Displacement of [3H]CP55940 from membrane homogenates of CHO cells expressing the 
human CB2 receptor. (B) Measurement of enhancement of [35S]GTPȖ6 ELQGLQJ LQ PHPEUDQH
homogenates of CHO cells expressing the CB2 receptor, expressed as a percentage of the response 
achieved by 1µM CP55940. The figures represent mean values ± SEMs of three independent 
experiments. 
 
